

Oxidative phosphorylation is required for cardiomyocyte re-differentiation and long-term fish heart regeneration

Received: 24 October 2023

Accepted: 26 August 2025

Published online: 1 October 2025

 Check for updates

Konstantinos Lekkos^{1,2}, Zhilian Hu^{1,2}, Phong D. Nguyen^{3,4}, Hessel Honkoop³, Esra Sengul^{1,2}, Rita Alonaizan^{1,2,5}, Jana Koth⁶, Jun Ying^{1,2,7}, Madeleine E. Lemieux⁸, Alisha Kenward^{1,2}, Sean Keeley⁹, Bastiaan Spanjaard^{10,11}, Brett W. C. Kennedy², Xin Sun^{1,2}, Katherine Banecki², Helen G. Potts², Gennaro Ruggiero^{1,2}, James Montgomery¹², Daniela Panáková^{10,13,14}, Jan Philipp Junker^{10,11,13}, Lisa C. Heather¹⁵, Xiaonan Wang¹⁵, Juan Manuel Gonzalez-Rosa^{9,16}, Jeroen Bakkers^{3,17} & Mathilda T. M. Mommersteeg^{1,2}✉

In contrast to humans, fish can fully regenerate their hearts after cardiac injury. However, not all fish have the same regenerative potential, allowing comparative inter-species and intra-species analysis to identify the mechanisms controlling successful heart regeneration. Here we report a differential regenerative response to cardiac cryo-injury among different wild-type zebrafish strains. Correlating these data with single-cell and bulk RNA sequencing data, we identify oxidative phosphorylation (OXPHOS) as a positive regulator of long-term regenerative outcome. OXPHOS levels, driven by glycolysis through the malate-aspartate shuttle, increase as soon as cardiomyocyte proliferation decreases, and this increase is required for cardiomyocyte re-differentiation and successful long-term regeneration. Reduced upregulation of OXPHOS in *Astyanax mexicanus* cavefish results in the absence of a dynamic temporal sarcomere gene expression program during cardiomyocyte re-differentiation. These findings challenge the assumption that OXPHOS inhibits regeneration and reveal targetable pathways to enhance heart repair in humans after myocardial infarction.

The ability for heart regeneration during adult life varies considerably among species. Mammals, including humans, have very limited regenerative capacity in the heart, whereas other species, including zebrafish, can completely restore damaged tissue^{1,2}. The current stance in the field is that this difference is underpinned by species-specific variations in cardiomyocyte metabolism^{3,4}. After birth, mammals are exposed to an oxygen-rich environment in comparison to the more hypoxic conditions in utero, resulting in a switch from a glycolytic

metabolism to OXPHOS largely fueled by fatty acid β -oxidation. This allows cardiomyocytes to meet the increased demand for cardiac output in warm-blooded species⁵ but also generates reactive oxygen species (ROS), which can damage DNA. As a result, cardiomyocytes that were highly proliferative before birth lose this ability after the first weeks of life^{6,7}. By contrast, fish live in water that has lower levels of oxygen than the surrounding air, which is thought to facilitate glycolytic metabolism throughout adulthood. Cold-blooded fish

A full list of affiliations appears at the end of the paper. ✉e-mail: mathilda.mommersteeg@dpag.ox.ac.uk

have lower cardiac output, and it has been suggested that the cardiomyocytes are less specialized; therefore, they do not require the high levels of ATP produced by OXPHOS and do not compromise on proliferative capacity. By using glycolysis, zebrafish cardiomyocytes can pass their cell cycle checkpoints and divide, restoring the lost myocardium after injury^{7–12}.

Numerous findings have confirmed the beneficial role of glycolysis during heart regeneration in fish. Glycolysis is strongly upregulated in the cardiomyocytes bordering the injured area, and, when inhibited, cardiomyocyte proliferation is reduced¹³. Additionally, uncoupling glycolysis from pyruvate oxidation, by preventing glucose from shunting toward OXPHOS through overexpression of *pdh* (pyruvate dehydrogenase kinase), increases cardiomyocyte proliferation¹⁴. However, the role of oxidative metabolism in the regenerative process remains elusive even though some studies have hinted that there is an upregulation of OXPHOS during heart regeneration^{15–17}. The reported increase in OXPHOS at 7 days post-cryo-injury (dpi), which coincides with the peak of cardiomyocyte proliferation¹⁸, seems counterintuitive and leaves many open questions about its role in regeneration.

Here, with an intra-species and inter-species comparative approach using zebrafish and *A. mexicanus*, we show that, during successful regeneration, OXPHOS is downregulated in the first days after injury while cardiomyocyte proliferation takes place. However, immediately after the peak of proliferation, the *malate-aspartate shuttle* (MAS) is upregulated, activating the *tricarboxylic acid* (TCA) cycle and OXPHOS. The upregulation of OXPHOS coincides with a dynamic pattern of re-differentiation of the border zone cardiomyocytes and determines the long-term regenerative outcome. Pharmacologically or genetically blocking the MAS or OXPHOS inhibits cardiomyocyte re-differentiation and regeneration. Therefore, the view on zebrafish heart regeneration as being solely reliant on glycolysis, with OXPHOS seen as exclusively detrimental, needs revisiting.

Results

Differential regenerative response among wild-type zebrafish strains

Although adult zebrafish can repair damaged heart muscle in response to cryo-injury, the speed of regeneration varies among studies^{19–25}. Those differences can be attributed to inter-study deviations in surgery techniques. However, the background strain used also varies, indicating possible differential responses to cryo-injury among strains. To identify potential intra-species variabilities in cardiac regeneration, we investigated the response of seven different wild-type zebrafish strains to cryo-injury. In addition to the strain already used in our facility (Kings College London (KCL)), we imported six zebrafish strains: AB, Nadia (NA), Sanger AB Tübingen (SAT), Tupfel long fin (TL), Tübingen (TU) and Wild India Kolkata (WIK) (Fig. 1a). Hearts were isolated at 1, 7, 21 and 90 dpi as well as uninjured controls and sham (Fig. 1a,b). Analysis of the uninjured hearts showed strong similarity among the strains but with some differences in morphology and transcriptome (Fig. 1a,c and Extended Data Fig. 1a,b). Despite the overall similarities, post-cryo-injury survival was significantly different among the strains (Extended Data Fig. 1c,d). To assess differences in regenerative response, we quantified the wound area and open wound length in all strains over time (Fig. 1d,e and Extended Data Fig. 1e–g). At 1 dpi, NA had significantly smaller wounds compared to other strains. At 7 dpi, no significant differences were observed; however, at 21 dpi, TU showed significantly larger wound area. At 90 dpi, when the cryo-injury-induced wound is reported to be strongly reduced or to have disappeared^{20,26}, there were large differences among the strains. TU and SAT had the largest wound area/length, whereas NA and TL had the smallest wounds (Fig. 1e and Extended Data Fig. 1e–g). Comparing the data between the different timepoints showed positive correlation among 7 dpi, 21 dpi and 90 dpi wound length/area but not 1 dpi (Fig. 1f and Extended Data Fig. 1h–j), indicating that any experimental variation in cryo-injury did

not influence end-stage regeneration. There was also no correlation between survival and the extent of injury (Extended Data Fig. 1k,l). These data indicate that the response to cryo-injury is heterogeneous among different wild-type zebrafish strains.

OXPHOS is beneficial for heart regeneration

To investigate whether the observed differences might uncover mechanisms underlying regeneration, we analyzed the 7 dpi RNA sequencing (RNA-seq) data to identify genes and enriched processes significantly correlating to wound area/length (Pearson's $r > 0.75$ or $r < -0.75$)²⁶. Unexpectedly, this identified *Oxidative phosphorylation* and *Respiratory transport, ATP synthesis by chemiosmotic coupling and heat production by uncoupling protein* (further referred to as OXPHOS) as the top enriched processes negatively correlating with 7 dpi wound length and 90 dpi wound area, respectively, suggesting that upregulated OXPHOS may promote cardiac regeneration (Fig. 1g,h, Extended Data Fig. 2a and Supplementary Tables 1 and 2). Oxygen consumption rate (OCR) measurements confirmed the functional upregulation of OXPHOS in the best regenerating strains at 14 dpi (Fig. 1i) but not before injury (Extended Data Fig. 2b). *Glycolysis and gluconeogenesis* (further referred to as *Glycolysis*) was also enriched in the genes negatively correlating to 7 dpi (subcategory of *Carbon metabolism*; Extended Data Fig. 2c and Supplementary Table 1) and correlated strongly with OXPHOS (Extended Data Fig. 2d), indicating that these processes are linked. Indeed, extracellular acidification rate (ECAR), a functional measurement of glycolytic flux, was highest in 14 dpi NA and TL with no differences before injury (Extended Data Fig. 2e,f). Identification of glutamate and lactate derived from the exogenous [¹³C₆]-glucose confirms that glucose is both anaerobically metabolized to lactate and aerobically oxidized within the TCA in 7 dpi KCL ventricles (Extended Data Fig. 2g,h). These data suggest a previously unidentified beneficial role for OXPHOS, driven by glucose oxidation, during heart regeneration.

Upregulation of the MAS drives OXPHOS and heart regeneration

By reanalyzing published single-cell RNA sequencing (scRNA-seq) datasets from Hu et al.²⁷ and Honkoop et al.¹³, we confirmed that OXPHOS was highest in border zone cardiomyocytes (Fig. 2a,b)¹³. To test whether OXPHOS is indeed beneficial for regeneration, we treated KCL fish with rotenone, which inhibits complex I of the respiratory electron transport chain (ETC). Rotenone treatment resulted in larger wounds at 21 dpi compared to control DMSO-treated fish (Fig. 2c and Extended Data Fig. 3a). These data indicate that upregulation of OXPHOS in border zone cardiomyocytes is not detrimental to regeneration, as previously thought, and may be required for optimal regeneration.

To identify the mechanism underlying the upregulation of OXPHOS, we plotted OXPHOS over time in the different strains (Fig. 2d). This showed that, after an initial dip at 1 dpi, in contrast to the other strains, OXPHOS levels did not recover at 7 dpi in TU and SAT (largest 90 dpi wounds). To analyze if this lack of recovery was due to mitochondrial dysfunction, we performed electron microscopy of cardiomyocytes in SAT and WIK. Although mitochondria in WIK showed a similar morphology in both border zone and remote zone cardiomyocytes, the mitochondria in SAT were more swollen and disorganized in the border zone compared to the remote zone, which are hallmarks of mitochondrial failure (Extended Data Fig. 3b)^{13,28}. Plotting the genes uniquely upregulated or downregulated in both SAT and TU strains at 7 dpi identified the cytoplasmic malate dehydrogenase gene *mdh1ab*, which was also the top gene negatively correlating to 90 dpi wound length (Fig. 2e,f and Extended Data Fig. 3c,d). scRNA-seq data confirmed *mdh1ab* to be mainly expressed in cardiomyocytes (Extended Data Fig. 3e).

Mdh1 is important for maintaining the balance of NAD⁺/NADH between the cytosol and the mitochondria as part of the MAS




Fig. 1 | Differential regenerative response to cryo-injury among wild-type adult zebrafish strains identifies OXPHOS as beneficial for regeneration.

a, Representative images of adult wild-type zebrafish strains (scale bar, 1 cm) and their intact heart, including atrium (A), bulbus arteriosus (BA) and ventricle (V) (scale bar, 500 μm). **b**, Experimental procedure to harvest and assay zebrafish hearts prior to and after cryo-injury. **c**, Correlation matrix of bulk RNA-seq data on uninjured ventricles showing a strong correlation between strains. **d**, Representative AFOG image of an AB heart at 7 dpci indicating wound area and open wound length measurements (scale bar, 300 μm). **e**, Wound area quantification of the seven wild-type strains showed significant differences at 1, 21 and 90 dpci among the strains. **f**, Positive correlation between 7 dpci wound

length and 90 dpci wound area. **g**, The top five enriched processes in the genes negatively correlating to wound length at 7 dpci and area at 90 dpci in the 7 dpci bulk RNA-seq. **h**, Significant negative correlation between 7 dpci wound length and OXPHOS. **i**, OCR measurements of 14 dpci ventricles show significant differences in OXPHOS among the seven wild-type zebrafish strains. **c**, $n = 3$ biological replicates per zebrafish strain; **e**, 1 dpci: AB, NA, SAT, TL, TU, WIK $n = 7$; KCL $n = 8$. 7 dpci: NA, SAT, TL, TU, WIK $n = 7$; AB, KCL $n = 8$. 21 dpci: SAT, WIK $n = 7$; AB $n = 6$; NA $n = 11$; TL $n = 9$; TU $n = 5$; KCL $n = 8$. 90 dpci: AB, NA, SAT, TL, WIK $n = 7$; TU $n = 6$; KCL $n = 8$ (biological replicates). **i**, $n = 5$ biological replicates per strain. **e, i**, One-way ANOVA with Tukey's test. **f–h**, Simple linear regression. **g**, Analysis performed using Metascape. CM, cardiomyocyte.

(Extended Data Fig. 3f)²⁹. High levels of MAS activity (as in NA) allow for recycling of NAD⁺ in the cytosol, which can feed back into glycolysis with simultaneous regeneration of NADH in the mitochondria fueling the TCA cycle and OXPHOS. Therefore, although NAD⁺ can also be replenished by lactate secretion under anaerobic conditions, the net result of low levels of MAS (as in SAT) could result in less glycolysis as well as less OXPHOS (Figs. 1i and 2g and Extended Data Fig. 2d,e). In line with this, MAS levels correlated with levels of OXPHOS in the highly regenerative NA, but this correlation was absent in the poorly regenerating SAT strain (Fig. 2h,i). Moreover, although Glycolysis generally correlated with OXPHOS, this was disrupted in the SAT strain (Fig. 2j). As the MAS provides malate into the second span of the TCA cycle, a source of acetyl CoA is simultaneously required for TCA cycling. Although we showed that this acetyl CoA can be supplied by glucose, this does not exclude contribution from fatty acid β -oxidation. Indeed, we found that MAS gene expression levels also correlated with the levels of fatty acid β -oxidation, and this was again absent in the SAT (Fig. 2k). This indicates that, although the MAS is driven by glycolysis, its activation of the TCA cycle allows for a general increase in mitochondrial metabolism, including activation of biosynthetic pathways, which we confirmed by comparing NA and SAT using Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis and genetic-scale metabolic modeling (Extended Data Fig. 3g,h and Supplementary Tables 3 and 4). To confirm the importance of the MAS for regeneration, we exposed KCL fish to the small-molecule inhibitor PF-04859989 to block the MAS³⁰, which resulted in reduced regeneration compared to DMSO-treated controls (Fig. 2i and Extended Data Fig. 3f,i). These data indicate that glycolysis and mitochondrial metabolism are tightly coupled via the MAS and that activation of the MAS is required for regeneration.

OXPHOS is not required for cardiomyocyte proliferation

The established increase in OXPHOS in regenerative border zone cardiomyocytes seems paradoxical as OXPHOS is thought to cause cell cycle arrest⁷. To investigate this, we quantified cardiomyocyte proliferation across the strains at 7 dpci and 21 dpci. The reported peak of cardiomyocyte proliferation is 7 dpci, which declines toward baseline by 21 dpci³¹. At 7 dpci, only WIK had significantly more proliferating cardiomyocytes in the border zone myocardium compared to the other strains. At 21 dpci, proliferation had strongly reduced, and this difference was absent (Fig. 3a,b). TL, one of the best regenerating strains at 90 dpci, had the lowest percentage of proliferation at both 7 dpci and 21 dpci (Fig. 3b). Levels of border zone proliferation correlated between 7 dpci and 21 dpci (Fig. 3c). Surprisingly, however, 7 dpci border zone proliferation did not correlate to 21 dpci or 90 dpci wound size (Fig. 3d and Extended Data Fig. 4a). Removing the 'outlier' WIK did not influence these results, indicating that the lack of correlation with 90 dpci wound size was not solely driven by the WIK measurements (Extended Data Fig. 4b). Correspondingly, there was no overlap between the genes correlating to border zone proliferation and 90 dpci wound size

(Fig. 3e, arrowhead; Extended Data Fig. 4c,d; and Supplementary Table 5), and no correlation between proliferation and levels of OXPHOS was observed (Fig. 3f). We also did not find a correlation with levels of Glycolysis (Fig. 3g). Indeed, treating KCL fish with inhibitors PF-04859989 against the MAS, rotenone against complex I of the ETC or control DMSO between 3 dpci and 7 dpci showed no difference in cardiomyocyte proliferation at 7 dpci (Fig. 3h). High levels of proliferation in the WIK were reflected in the largest reduction in wound length between 7 dpci and 21 dpci (Fig. 3i). However, regeneration stalled after 21 dpci, and none of the hearts had fully regenerated by 90 dpci (Fig. 3j and Extended Data Figs. 1e and 4e). Therefore, cardiomyocyte proliferation plays a limited role during long-term regeneration, consistent with the knowledge that proliferation peaks at 7 dpci and substantially declines long before regeneration is completed³¹. These data suggest that increased OXPHOS is required for optimal cardiac regeneration after cessation of proliferation.

Levels of OXPHOS correlate with the upregulation of border zone embryonic sarcomere expression

As OXPHOS levels increase with cardiomyocyte differentiation³², and border zone cardiomyocytes de-differentiate and re-differentiate during regeneration^{33,34}, we next analyzed the differentiation state of the border zone myocardium in which we identified OXPHOS activity. Embryonic cMHC antibody (embcmhc) (embryonic cardiac myosin heavy chain (emcmhc), N2.261c) has been used to stain border zone cardiomyocytes, and its expression is considered to reflect their immature, embryonic state^{18,35}. Staining with this antibody showed large differences among the strains at both 7 dpci and 21 dpci (Fig. 4a,b). Especially notable was that, although expression in NA and WIK was similar at 7 dpci, it remained high at 21 dpci in NA but strongly declined in WIK, in which regeneration stalls at that stage (Fig. 4a,b and Extended Data Fig. 1e). By contrast, TU had low expression levels at 7 dpci, which further declined by 21 dpci, and expression was not evident in SAT at either stage (Fig. 4a,b). Border zone embcmhc expression at 7 dpci correlated with 7 dpci and 90 dpci wound length, whereas 21 dpci embcmhc correlated with 90 dpci wound area (Fig. 4c,d). OXPHOS appeared to be driving embcmhc expression at 7 dpci and 21 dpci (Fig. 4e and Supplementary Tables 6 and 7). Glycolysis and MAS gene expression positively correlated with 7 dpci embcmhc expression (Fig. 4e,f). Accordingly, there was significantly reduced embcmhc expression upon inhibition of the MAS (PF-04859989) or OXPHOS (rotenone) compared to DMSO control (Fig. 4g). Border zone embcmhc levels did not correlate to border zone proliferation (Fig. 4h). There was an overlap between genes correlating to 7 dpci embcmhc expression and 90 dpci wound length but not proliferation (Fig. 4i, arrowhead). These data reveal that higher and prolonged expression of embcmhc¹⁸ is beneficial for long-term regeneration.


It seems counterintuitive that both MAS and OXPHOS appear to be required for this embryonic state, as embryonic cardiomyocytes have been shown to strongly rely on glycolysis instead of OXPHOS for

Fig. 2 | Upregulation of the MAS drives OXPHOS and regeneration. **a**, OXPHOS gene expression is highest in cardiomyocytes compared to other cell types in scRNA-seq of AB/TL—reanalysis of Hu et al.²⁷. **b**, Positive correlation between Glycolysis and OXPHOS in 7 dpci cardiomyocytes, with highest levels of both in the border zone cardiomyocytes (red), by reanalyzing scRNA-seq data of TL published previously by Honkoop et al.¹³. Clusters 1, 2, 4 and 7 refer to the clustering in the original publication. **c**, Increased wound length in KCL treated with rotenone in comparison to DMSO control at 21 dpci. **d**, Temporal pattern of OXPHOS gene expression in the bulk RNA-seq data. **e**, Venn diagram indicating uniquely differentially expressed (DE) genes in TU and SAT (AB and KCL not shown but included in analysis) with heatmap of the top DE genes in the bulk RNA-seq identifying *mdh1ab* uniquely downregulated in TU and SAT versus the other strains. **f**, Expression pattern of *mdh1ab* over time in the bulk RNA-seq data of the strains. **g**, Schematic diagram indicating the influence of activated

MAS on maintaining cytosolic and mitochondrial balance of NAD⁺/NADH in NA versus SAT. **h,i**, Positive correlation between the MAS and OXPHOS in the NA strain (**h**) but not the SAT strain (**i**). **j,k**, Positive correlation of Glycolysis with OXPHOS (**j**) and MAS versus Fatty Acid (FA) oxidation (**k**) in all strains but absence of correlation in SAT. **l**, Wound length quantification showing increased 21 dpci wound length in KCL hearts treated with MAS inhibitor PF-04859989 in comparison to DMSO control. **c**, Rotenone $n = 4$, DMSO $n = 5$ (biological replicates); **d,f**, uninjured: $n = 3$ per strain, 1 dpci: SAT, TU $n = 2$, AB, NA, TL, WIK, KCL $n = 3$, 7 dpci $n = 3$ per strain (biological replicates); **e**, $n = 3$ biological replicates per strain; **l**, $n = 5$ biological replicates per group. **b,h–k**, Simple linear regression. **c,l**, Unpaired two-tailed Student's t -test. **d,f**, Two-way ANOVA with Tukey's test; data presented as mean $\pm$ s.e.m. BL, ves. EC, blood vessel endothelial cell; BZ, border zone; C, cluster; CM, cardiomyocyte; incl., including; RZ, remote zone; Uninj, uninjured.

their metabolism^{36,37}. However, reanalysis of published bulk RNA-seq data of zebrafish heart development between 30 hours and 72 hours post-fertilization (hpf) from Hill et al.³⁸ showed that *OXPHOS* genes are progressively upregulated during development, indicating that *OXPHOS* increases with cardiomyocyte maturation (Extended Data

Fig. 5a). Furthermore, directly comparing 2 days post-fertilization (dpf) embryonic ventricular cardiomyocytes with 7 dpf border zone cardiomyocytes, using previously published integrated scRNA-seq data¹³, shows that *OXPHOS* levels in embryonic cardiomyocytes are similar to border zone cardiomyocytes and much higher than in remote






Fig. 3 | OXPPOS is not required for cardiomyocyte proliferation.

a, Representative images of immunofluorescence staining showing Mef2*PCNA⁺ double-positive proliferating cardiomyocytes in TU and WIK at 7 dpci. Framed areas highlight the wound border zone (red) (scale bar, 300 μm). **b**, Quantification of Mef2*PCNA⁺ double-positive cells showing differences in proliferating cardiomyocytes in the border zone at 7 dpci but not at 21 dpci. **c**, Positive correlation of percentage of proliferating cardiomyocytes in the border zone between 7 dpci and 21 dpci. **d**, No correlation between 7 dpci border zone proliferation and 90 dpci wound length. **e**, Venn diagram displaying complete lack of overlap between genes correlating to 7 dpci border zone proliferation and 90-dpci wound length. **f, g**, No correlation between border zone proliferation and *OXPPOS* (**f**) or *Glycolysis* (**g**) at 7 dpci. **h**, Quantification of Mef2*PCNA⁺ cells showing no difference in proliferating cardiomyocytes in the border zone of 7 dpci KCL adult treated with inhibitor PF-04859989 or rotenone

compared to DMSO control. **i**, Temporal wound length reduction of all strains between 1, 7, 21 and 90 dpci. Arrow highlighting the strong decrease in wound length in WIK between 7 dpci and 21 dpci. **j**, Percentage of hearts completely regenerated at 90 dpci or with closed compact wall but remaining internal scar or with open compact wall and internal scar remaining. **b, 7 dpci**: AB, NA, TU $n = 7$; SAT, WIK $n = 6$; TL $n = 5$; KCL $n = 3$, 21 dpci: AB, SAT, TL, TU $n = 5$; NA $n = 6$; WIK $n = 7$; KCL $n = 8$ (biological replicates); **h**, PF-04859989, DMSO $n = 6$, rotenone $n = 5$ (biological replicates); **i**, AB: 1, 90 dpci $n = 7$; 7 dpci $n = 8$; 21 dpci $n = 6$. NA: 1, 7, 90 dpci $n = 7$; 21 dpci $n = 11$. SAT: 1, 7, 21, 90 dpci $n = 7$. TL: 1, 7, 90 dpci $n = 7$; 21 dpci $n = 9$. TU: 1, 7 dpci $n = 7$; 21 dpci $n = 5$; 90 dpci $n = 6$. WIK: 1, 7, 21, 90 dpci $n = 7$. KCL: 1, 7, 21, 90 dpci $n = 8$ (biological replicates); **j**, AB, NA, SAT, TL, WIK $n = 7$; TU $n = 6$; KCL $n = 8$. **b, h**, One-way ANOVA with Tukey's test. **c, d, f, g**, Simple linear regression. **h**, Two-way ANOVA with Tukey's test. **i**, Data presented as mean $\pm$ s.e.m. Mef2, myocyte enhancer factor 2; PCNA, proliferating cell nuclear antigen.

zone cardiomyocytes (Fig. 4j). This indicates that *OXPPOS* levels indeed return to an embryonic state, but *OXPPOS* levels are unexpectedly high in cardiomyocytes during active (re-)differentiation. Upregulation of *OXPPOS* genes would facilitate the increase in proteins required for assembly of the ETC while mitochondrial numbers scale up to generate the energy required for sarcomere reassembly and maturation. The maintained high expression of *embcmhc* in strains such as NA and TL at 21 dpci indicates that a continued 'embryonic' re-differentiation state

is beneficial for successful long-term regeneration, after proliferation levels have ceased.

Temporal separation of cardiomyocyte proliferation, *OXPPOS* and re-differentiation

Consistent with a correlation between long-term regeneration and cardiomyocyte re-differentiation, *Cardiac muscle contraction* as a Gene Ontology term was also enriched at 7 dpci (Fig. 4e, red). Although most




Fig. 4 | Levels of OXPHOS correlate to the upregulation of embryonic myosin.

a, Representative images of MF20 and embcmhc double immunofluorescence staining showing differential embryonic myosin staining in the border zone cardiomyocytes of NA, WIK, TU and SAT at 7 dpci and 21 dpci (scale bar, 300 μ m). **b**, Quantification of differential expression of embcmhc in the border zone of the strains at 7 dpci and 21 dpci. **c, d**, Negative correlation between 7 dpci border zone embcmhc staining with 7 dpci wound length (**c**) and 21 dpci border zone embcmhc staining with 90 dpci wound area (**d**). **e**, Top five positively correlating terms in genes of 7 dpci bulk RNA-seq with 7 dpci and 21 dpci border zone embcmhc activity. **f**, Positive correlation of embcmhc staining to MAS at 7 dpci. **g**, Reduced border zone embcmhc expression in 7 dpci KCL hearts treated with inhibitors PF-04859989 or rotenone compared to DMSO control. Representative images are on the left, and quantification is on the right (scale bar, 300 μ m).

h, No correlation between embcmhc activity and border zone cardiomyocyte proliferation at 7 dpci. **i**, Venn diagram displaying high overlap between genes correlating to 90 dpci wound length and 7 dpci embcmhc level but little overlap between embcmhc and border zone cardiomyocyte proliferation at 7 dpci. **j**, Levels of OXPHOS in adult 7 dpci remote and border zone cardiomyocytes and 2 dpf embryonic ventricular cardiomyocytes, showing similar levels of OXPHOS in border zone and embryonic cardiomyocytes. Reanalysis of previously published integrated scRNA-seq dataset¹³. **b, 7 dpci**: AB $n = 8$; NA, SAT, WIK $n = 7$; TL, TU, KCL $n = 6$, 21 dpci: AB, SAT, WIK $n = 6$; NA, KCL $n = 8$; TL $n = 9$; TU $n = 5$ (biological replicates); **g**, DMSO, PF-04859989 $n = 6$, rotenone $n = 4$ (biological replicates). **b, g**, One-way ANOVA with Tukey's test. **c, d, f, h**, Simple linear regression. **e**, Analysis performed using Metascape. BZ, border zone; c, cluster; Embr. V. CM, embryonic ventricular cardiomyocyte; MF20, all cardiomyocytes; RZ, remote zone.

of the genes in this term were OXPHOS genes, selecting only the genes with a specific role in muscle contraction showed that these were most strongly expressed in border zone cardiomyocytes and correlated to levels of OXPHOS (Fig. 5a and Extended Data Fig. 5b, c). By contrast, there was no correlation of expression of proliferation marker *mcm5* to levels of border zone Cardiac muscle contraction (Fig. 5b), indicating that proliferation and differentiation are mutually exclusive. To understand the timeline of events, we performed an scRNA-seq experiment using the *TgBAC(nppa:mCitrine)^{88891g}* line (TL background)¹³,

in which mCitrine is expressed in border zone cardiomyocytes under the *nppa* promoter. mCitrine⁺ cardiomyocytes at 1, 3 and 7 dpci were FACS sorted and processed for scRNA-seq (Fig. 5c and Supplementary Information). Initial analysis identified seven clusters that appeared to be grouped according to the injury timepoints (Extended Data Fig. 5d–f and Supplementary Table 8). We confirmed that the cells were border zone cardiomyocytes and that a subcluster was entering the cell cycle (Extended Data Fig. 5g–i). To investigate the order of events that border zone cardiomyocytes undergo during regeneration,




Fig. 5 | Cardiomyocyte proliferation is separated in time from OXPHOS and cardiomyocyte re-differentiation. **a,b**, Positive correlation of cardiac muscle contraction genes in cardiomyocytes to OXPHOS (**a**) but not to proliferation marker *mcm5* (**b**) by reanalyzing previous scRNA-seq data from Honkoop et al.¹³. Red indicates border zone cardiomyocytes; clusters are as in the original publication. **c**, Schematic diagram of the scRNA-seq procedure using the transgenic *TgBAC(nppa:mCitrine)* line to FACS 1 dpi, 3 dpi and 7 dpi border zone cardiomyocytes. **d**, Timeline generated by pseudotime analysis of the 1 dpi, 3 dpi and 7 dpi border zone cardiomyocytes. **e**, Pseudotime analysis recapitulates the real-time order of the samples. **f**, Differentially expressed genes changing over pseudotime, grouped into eight modules using unsupervised hierarchical clustering. Each module was analyzed for enriched processes. **g**, Schematic to indicate how levels of OXPHOS and Cell cycle genes alternate.

h, StemID analysis shows that the cardiomyocytes differentiate along the pseudotime. **i**, Sequential activation of Glycolysis, TCA cycle, MAS and OXPHOS genes based on pseudotime analysis. **j**, Correlation graphs of strain bulk RNA-seq data comparing significantly expressed genes in modules 3 and 6 with proliferation (*pcna*), differentiation state (*entropy*), Glycolysis, OXPHOS, *tnnc1a* (correlates to border zone embcmhc expression) and *myl7* (mature cardiomyocyte marker). Data showing positive correlation between proliferation and de-differentiation with module 3 but negative correlation to module 6. OXPHOS and *myl7* have the opposite pattern. Embryonic border zone marker *tnnc1a* only positively correlates to module 6 and, thus, the re-differentiation stage. **d-f,h**, $n = 4$ hearts per timepoint. **a,b,j**, Simple linear regression. BZ, border zone; CM, cardiomyocyte; RZ, remote zone.




Fig. 6 | Genetic manipulation of *mdh1ab* confirms its role during long-term regeneration and cardiomyocyte re-differentiation. **a**, Representative images of RNA scope analysis of AB cardiomyocyte-specific *mdh1ab* knockout and *cardiodeleter* control showing absence of *mdh1ab* mRNA in the MF20⁺ myocardium in the knockout. **b**, Representative images of AFOG staining on AB cardiomyocyte-specific *mdh1ab* knockout and *cardiodeleter* control with wound area quantification showing increased 21 dpci wound area in the *mdh1ab* knockout but not the *mdh1aa* knockout in comparison to controls. **c**, Representative images of embchmc immunohistochemistry on AB cardiomyocyte-specific *mdh1ab* knockout and *cardiodeleter* control, with quantification showing reduced presence of embchmc in the knockout compared to control. **d**, Quantification of PCNA⁺ border zone cardiomyocytes indicates no differences in proliferation between the AB cardiomyocyte-specific *mdh1ab* knockout and the *cardiodeleter* control. **e**, Representative images of RNA scope analysis of KCL cardiomyocyte-specific *mdh1ab* overexpression and GFP control showing increased levels of *mdh1ab* mRNA in the MF20⁺ myocardium in the overexpression heart. **f**, Representative images of AFOG staining on KCL

cardiomyocyte-specific *mdh1ab* overexpression and GFP control, with wound area quantification showing reduced 21 dpci wound area in the *mdh1ab* overexpression model compared to controls. **g**, Representative images of embchmc immunohistochemistry on KCL cardiomyocyte-specific *mdh1ab* overexpression and GFP control, with quantification showing reduced presence of embchmc in the overexpression hearts compared to control. **h**, Quantification of PCNA⁺ border zone cardiomyocytes indicate no differences in proliferation between the KCL cardiomyocyte-specific *mdh1ab* overexpression and GFP control. **i**, OCR measurements of 14-dpci ventricles show increased levels of OXPHOS in the overexpression hearts compared to control (scale bars, 100 μ m). **b**, *mdh1ab* cKO $n = 9$, *mdh1aa* cKO $n = 11$, *cardiodeleter* $n = 12$ (biological replicates); **c**, *mdh1ab* cKO $n = 9$, *cardiodeleter* $n = 8$ (biological replicates); **d**, *mdh1ab* cKO $n = 9$, *cardiodeleter* $n = 11$ (biological replicates); **f**, *mdh1ab* cOE $n = 6$, GFP cOE $n = 7$ (biological replicates); **i**, $n = 8$ biological replicates per group. **b**, One-way ANOVA with Tukey's test. **c**, **f**, **i**, Unpaired one-tailed Welch's *t*-test. **d**, **h**, Unpaired two-tailed Student's *t*-test. **g**, **i**, Unpaired one-tailed Student's *t*-test. BZ, border zone; CM, cardiomyocyte.

cells were projected into a linear pseudotime trajectory (Fig. 5d,e). We identified the genes that were differentially expressed over the pseudotime and grouped them with unsupervised hierarchical clustering into eight modules that were analyzed for enriched processes (Fig. 5f and Supplementary Tables 9–17). At 1 dpci, there was high expression of genes involved in *Glycolysis*, including *hk1*, encoding for a rate-limiting enzyme for glycolysis, and *pdk4*, encoding for an enzyme that inhibits pyruvate entry into the TCA cycle, likely due to cellular stress directly in response to injury (module 1)^{39,40}. Between 1 dpci and 3 dpci, *OXPHOS* genes were downregulated, whereas *Glycolysis* continued (module 2). During the transition from 3 dpci to 7 dpci, *Cell cycle* genes were upregulated (module 3). The peak of *Cell cycle* gene expression was directly followed by *Mitochondrial organisation* (module 4) and expression of large numbers of *OXPHOS* genes (module 5). *OXPHOS* as well as *Glycolysis* remained active toward the end of the 7-dpci timepoint (module 6). This was followed by further *Mitochondrial organisation* (module 7), possibly reflecting mitochondrial recovery¹⁵, and by *Membrane organisation*, suggesting cardiomyocyte remodeling, possibly to invade the wound (modules 8)^{41–44}. These data indicate that when *OXPHOS* levels were lowest, *Cell cycle* was active (Fig. 5f,g). We then used the StemID algorithm, which revealed an increase in cardiomyocyte differentiation state along the pseudotime (lower diversity of cell fates and lower transcriptome entropy; Fig. 5h). Looking in detail at *Glycolysis*, *TCA* and *OXPHOS* genes in the pseudotime suggests sequential activation of the pathways (Fig. 5i). Although some *OXPHOS* and *TCA* genes were expressed in the initial injury response around the time of *Cell cycle* activity, the metabolic flow appeared to go toward lactate (module 4), followed by a sudden switch to genes of the MAS and TCA cycle in module 5 and a sudden strong upregulation of *OXPHOS* genes (Fig. 5f,g, black line). These data confirm that proliferation and *OXPHOS* are separated in time. Specific upregulation of MAS at the start of *OXPHOS* in the pseudotime supports our finding of a key role for the MAS in the activation of *OXPHOS* at 7 dpci.

Integrating the pseudotime data with the bulk RNA-seq of the different strains allowed us to plot the pseudotime modules against the processes of interest in the bulk RNA-seq (Fig. 5j and Extended Data Fig. 6). This revealed that genes from modules 1–3 positively correlated with both *pcna* and *entropy* levels (the higher the entropy, the more de-differentiated the cells) but negatively with levels of mature cardiomyocyte marker *myl7*, confirming that, during modules 1–3, cardiomyocytes de-differentiate and proliferate. There was a weak negative correlation to *OXPHOS* and no correlation to *Glycolysis*. In module 4, these correlations disappeared while reversing from module 5 onwards. Modules 5–7 showed a negative correlation to *pcna* and *entropy* and a positive correlation to *myl7*, indicating cardiomyocyte re-differentiation and cell cycle exit. There was a strong correlation between levels of *Glycolysis* and *OXPHOS* with these later modules. The marker of embcmhc expression, *tnnc1a*, did not correlate to the early pseudotime or to module 3, when the cells are most de-differentiated, indicating that it is not a de-differentiation marker. By contrast, it correlated to modules 5–7, confirming that upregulation of embryonic sarcomere genes and *OXPHOS* are specific for cardiomyocyte re-differentiation.

Fig. 7 | Strongly reduced re-differentiation gene expression in *A. mexicanus* cavefish versus surface fish. a, b, Top five enriched processes upregulated in surface fish at 7 dpci (a) and 30 dpci (b) compared to cavefish. **c–f**, Positive correlation of TCA/OXPHOS with *Glycolysis* genes at all timepoints in surface fish (c and e) but only up to 7 dpci in cavefish (d and f). **g, h**, Expression over time in bulk RNA-seq data. Although TCA/OXPHOS genes are initially relatively similarly expressed, they dip in cavefish at 7 dpci. From 7 dpci onwards, there is a steady increase until at least 30 dpci (g). Expression of MAS genes follows a similar pattern as TCA/OXPHOS expression (h). **i, j**, Significant positive correlation between the MAS and *Glycolysis* at late timepoints in surface fish (h) but not in cavefish (i). **k–m**, Expression over time in bulk RNA-seq data of two genes correlating to embcmhc expression in zebrafish, *acta1* (k) and *tnnc1a* (l),

Genetic manipulation of *mdh1ab* confirms its role in long-term regeneration

Our data indicate that activation of the MAS and OXPHOS are key for re-differentiation and long-term regeneration. However, as both inhibitors might have off-target effects^{30,45,46}, we generated cardiomyocyte-specific knockouts (cKO) for *mdh1ab* (*mdh1ab* cKO, AB strain) (Fig. 6a). To generate the knockout, we injected a construct containing three gRNAs to remove the entire *mdh1ab* gene into a *cardiodeleter* line expressing Cas9 under control of the *myl7* promoter⁴⁷. Quantification of wound size at 21 dpci showed reduced regeneration in the *mdh1ab* cKO, but not the *mdh1aa* cKO, compared to control *cardiodeleters*, confirming our findings using the MAS inhibitor (Fig. 6b). Further quantification of the hearts for embcmhc showed a strong reduction in embcmhc staining in the border zone cardiomyocytes in absence of *mdh1ab* (Fig. 6c), whereas cardiomyocyte border zone proliferation was unaffected (Fig. 6d and Extended Data Fig. 7a). To understand if manipulating *mdh1ab* could result in enhanced regeneration, we also generated a cardiomyocyte-specific *mdh1ab*-overexpressing line (*mdh1abcOE*, KCL strain) (Fig. 6e). Overexpression in cardiomyocytes indeed resulted in enhanced regeneration compared to green fluorescent protein (GFP)-overexpressing controls (Fig. 6f). Correspondingly, embcmhc was increased, whereas proliferation was again not different (Fig. 6g,h and Extended Data Fig. 7b). To confirm the role of *mdh1ab* in the upregulation of OXPHOS, we measured the OCRs of the overexpression and control hearts at 14 dpci, which indeed showed increased OXPHOS rates (Fig. 6i). Together, these data validate the role of the MAS in the upregulation of OXPHOS, cardiomyocyte differentiation and successful regeneration.

Reduced upregulation of OXPHOS and initiation of border zone re-differentiation in cavefish

To confirm our findings and to investigate potential evolutionary conservation of a beneficial role of OXPHOS during heart regeneration, we used *A. mexicanus*. We confirmed our previous findings that the surface fish population of *A. mexicanus* can regenerate its heart after ventricular resection, whereas the Páchon cavefish population forms a permanent scar⁴⁸ using cryo-injury (Extended Data Fig. 8a,b). Next, we performed bulk RNA-seq on *A. mexicanus* hearts from 6 hours to 30 dpci. Analysis of the top enriched processes revealed the terms *The citric acid cycle and respiratory electron transport* and *Oxidative phosphorylation* (further referred to as TCA/OXPHOS) as the most strongly upregulated processes at late timepoints in the regenerative surface fish compared to cavefish (7, 14 and 30 dpci; Fig. 7a,b, Extended Data Fig. 8c and Supplementary Tables 18–20). In the first 7 days after injury, levels of TCA/OXPHOS correlated to the levels of *Glycolysis* in both surface fish and cavefish (Fig. 7c,d); however, this was lost in cavefish at later timepoints (Fig. 7e,f), similar to the observation in the SAT zebrafish strain.



There was a steady increase in TCA/OXPHOS from 7 dpci onwards in the regenerating surface fish, elevating above baseline and still at an upward trend at 30 dpci (Fig. 7g). In the scarring cavefish, levels of TCA/OXPHOS were similar to surface fish in the first 3 days; however, at 7 dpci, there was a sudden decline followed by an increase that

showing strong upregulation at late timepoints in surface fish but much lower and shorter upregulation in cavefish. Mature marker *myl7* expression reduces in the first days after injury, before increasing again from 7 dpci onwards (m). Selected significance is shown. n, Heatmap of sarcomere and myosin-related genes correlating to *acta1*, *tnnc1a* or *myl7* in surface fish. Timepoints of interest are highlighted with black box. a,b, n = 5 biological replicates per morph per timepoint; g,h,k–m, n = 3 for uninjured cavefish and surface fish, n = 5 per morph for all other timepoints (biological replicates). a,b, Analysis performed using Metascape. c–f,i,j, Simple linear regression. g,h,k–m, Two-way ANOVA with Sidak's multiple test; data presented as mean ± s.e.m. pos., positively. SF, surface fish.

was lower than the surface fish (Fig. 7g). *MAS* showed a very similar pattern to *OXPHOS* (Fig. 7h), and, whereas *MAS* correlated to *Glycolysis* at late timepoints in surface fish, this correlation was lost in cavefish (Fig. 7i,j), suggesting that glycolysis does not directly fuel into *OXPHOS* via the *MAS* anymore.

To understand if this could affect cardiomyocyte re-differentiation, we plotted sarcomere markers *acta1* and *tnnc1a* that correlated

to 7 dpci embcmhc expression in zebrafish over time in *Astyanax* (Fig. 7k,l)⁴⁴. In surface fish, *acta1* was upregulated at 7 dpci and started to decline after 14 dpci, whereas, in cavefish, the upregulation was lower, delayed and shorter (Fig. 7k). *Tnnc1a* was upregulated later and shorter than *acta1* in surface fish, at 14 dpci only, but completely absent in cavefish (Fig. 7l). This indicates that at the time when the correlation between *Glycolysis* and *OXPHOS* is lost, non-regenerative cavefish show



a dampened upregulation of temporary ‘embryonic’ sarcomere genes, similar to the zebrafish strains SAT and TU (least regenerative). Plotting mature sarcomere marker *myl7* expression confirmed the decline in the first days after injury when the cardiomyocytes are de-differentiating, before increasing steadily again from 7 dpci onwards, and with an upward trend at 30 dpci, signaling the maturation of sarcomeres during re-differentiation (Fig. 7m). We then looked for sarcomere genes correlating to *acta1*, *tnnc1a* or *myl7* in surface fish ($r > 0.7$), which showed that there was a dynamic temporary sarcomere gene program correlating to *acta1* and *tnnc1a* that was strongly reduced in cavefish (Fig. 7n and Extended Data Fig. 8d). Levels of ‘mature’ sarcomere genes correlating to *myl7* were upregulated in the later stages in cavefish but did not achieve the strong increase between 14 dpci and 30 dpci that was seen in surface fish (Fig. 7n). This shows that, during the re-differentiation phase in regenerative fish, a dynamic temporal sarcomere gene program is activated, which is dampened when *OXPHOS* levels fail to increase sufficiently.

Discussion

Inter-species comparisons are a powerful approach to discover novel mechanisms involved in regeneration. However, it is difficult to tease out causative pathways when comparing highly diverse species such as zebrafish and mouse. These difficulties disappear when performing intra-species comparisons⁴⁹. We previously showed the power of comparing within a species using *A. mexicanus* surface fish and cavefish, which led to the discovery of a conserved role for *Irrc10* during cardiomyocyte re-differentiation and regeneration^{34,48}. In the present study, we took this approach further by comparing seven different wild-type zebrafish strains. Although zebrafish is considered the model organism for adult heart regeneration research⁵⁰, we show that not all zebrafish regenerate equally. Taking advantage of the regenerative range observed in the different zebrafish strains and *A. mexicanus* has allowed us to understand seemingly contradicting processes of successful cardiomyocyte proliferation and upregulation of *OXPHOS* during heart regeneration.

By integrating single-cell and bulk RNA-seq zebrafish data to generate a timeline of events, we identify a downregulation of *OXPHOS* during de-differentiation of the border zone cardiomyocytes and confirm the maintenance of *Glycolysis* during proliferation^{13,14}. Cardiomyocyte proliferation peaks when *OXPHOS* levels are lowest, followed by a sudden increase in *OXPHOS* toward the end of day 7. As ROS generated by *OXPHOS* inhibit cardiomyocyte proliferation⁷, the upregulation of *OXPHOS* could function to prevent hyperplasia.¹⁴ After the peak at 7 dpci, cardiomyocyte proliferation levels return to baseline by 21–30 dpci³¹. This is consistent with our finding that cardiomyocyte proliferation is important for regeneration until 21 dpci, but its role is negligible at later stages. Although this window of proliferation appears relatively short, it is sufficient to restore cardiomyocyte numbers to pre-injury levels by 30 dpci³¹. Interestingly, high levels of proliferation do not necessarily correlate with successful long-term regeneration, as exemplified by the WIK strain, which, although highly proliferative, does not complete regeneration. Reducing *OXPHOS* through knockout of *cox7a1* increases cardiomyocyte proliferation and improves regeneration at 28 dpci⁵¹. However, long-term regeneration was not analyzed, and it will be interesting to investigate the ability of cardiomyocytes to re-differentiate in these knockouts.

In contrast to proliferation, expression of *embcmhc* correlates well to long-term regenerative outcome. *Embcmhc* expression has been considered a hallmark of de-differentiation of the border zone cardiomyocytes, as they revert to a more embryonic state^{18,35}. As embryonic cardiomyocytes are thought to largely rely on glycolysis, with low *OXPHOS* levels^{15,37}, the upregulation of *OXPHOS* in the border zone and correlation to *embcmhc* expression seemed counterintuitive. However, we found that embryonic *OXPHOS* levels are higher than those of adult cardiomyocytes away from the injury site and similar to those

of the border zone, indicating that *OXPHOS* levels are higher in actively (re-)differentiating cells, which are reassembling their sarcomeres, as compared to fully differentiated cardiomyocytes. Thus, border zone cardiomyocytes do indeed revert to an embryonic state, but, in contrast to current beliefs, this results in an upregulation of *OXPHOS* that is important for long-term regeneration.

Sarcomere gene isoforms are known to switch as development and cardiomyocyte maturation progresses, with embryonic isoforms downregulated in the adult heart and replaced by expression of mature isoforms^{34,52}. Our data in *Astyanax* show that this switch also occurs during re-differentiation, with high, but temporal, upregulation of many sarcomere isoforms between 7 dpci and 30 dpci, whereas levels of other mature isoforms slowly increase until they become the main isoforms at 30 dpci. Temporal ‘embryonic’ sarcomere gene expression is not only higher in regenerative surface fish versus non-regenerative cavefish but also longer in duration. Similarly, in zebrafish, high and prolonged expression of *embcmhc* is beneficial to regeneration and especially long-term outcome. The transient embryonic sarcomere profile could be required for functional cardiomyocyte assembly and reintegration within the three-dimensional continuously contracting cardiac muscle. Studies on isoform switching of sarcomeres in mice suggest that embryonic/fetal isoforms may be less stiff and rigid, which could promote cardiomyocyte migration and functional reintegration during cardiac repair⁵².

High levels of *OXPHOS* allow the border zone cardiomyocytes to complete a full differentiation process that mimics developmental maturation. If *OXPHOS* levels remain too low, full differentiation is not achieved, which fits well with the finding from zebrafish that, in contrast to those completely regenerated, incompletely regenerated hearts still contain immature cardiomyocytes near the wound at 90 dpci³¹. In contrast to zebrafish, non-regenerative mouse and human wound border zone cardiomyocytes fail to fully re-differentiate³⁴. Similarly, mouse cardiomyocytes that have de-differentiated due to transient exposure to constitutively active ERBB2 fail to fully re-differentiate⁵³. The lack of re-differentiation in adult mouse, but not zebrafish, cardiomyocytes seems ironic, knowing that the mouse heart relies heavily on use of *OXPHOS* for its energy⁵⁴.

Our data point to a central role for the MAS in the sudden upregulation of *OXPHOS*. The MAS, which indirectly transfers NADH into the mitochondria and regenerates NAD⁺ in the cytoplasm^{29,55}, ensures maximal ATP generation from carbohydrate substrates by coupling with the ETC, thereby capitalizing on the capacity for glycolytic metabolism in fish. Although our study focuses on the boost in *OXPHOS* generated by activation of the MAS, the increase in TCA metabolites will likely play a wider role, from mediating biosynthetic pathways to regulation of chromatin modifications that can impact cell state and function, which requires further investigation. With a much more limited ability to upregulate glycolysis⁵⁴, adult mouse cardiomyocytes can likely not fully benefit from activation of the MAS to obtain the levels of *OXPHOS* required for full sarcomere assembly. Our data show that cardiomyocytes undergo different phases during regeneration, with dynamic metabolic rewiring between the early and late stages. During the early stages, upregulation of glycolysis and downregulation of *OXPHOS* is key for successful cardiomyocyte proliferation. However, long-term completion of regeneration requires increased rates of *OXPHOS* during sarcomere reassembly and restoration of cardiac function, before returning to the pre-injury adult metabolic state. As *OXPHOS* has been considered detrimental to regeneration, our findings require a shift in thinking about approaches in targeting pathways to induce long-term heart repair in the human heart.

Methods

Animals

Zebrafish and *A. mexicanus* were used in this study. Six wild-type zebrafish strains—AB, NA, SAT, TL, TU and WIK—were obtained as embryos from the Zebrafish International Resource Center and

from John Postlethwait's laboratory (University of Oregon). KCL has been bred in our facility for more than 20 generations but originated from King's College London. The wild-type zebrafish and transgenic *TgBAC(nppa:mCitrine)^{8897g}* (ref. 13) and *Tg(myl7:NLS-GFP-2A-NLS-Cas9-NLS)^{bcz101g}* (*cardiodeleter*)⁴⁷ zebrafish lines were kept at 28 °C under a 10/14-hour light/dark cycle according to current guidelines⁵⁶. *A. mexicanus* surface and cavefish were maintained at 20–21 °C under a light/dark cycle of 12/12 hours. All procedures involving animals at the University of Oxford were carried out in compliance with the revised Animals (Scientific Procedures) Act 1986 in the United Kingdom and Directive 2010/63/EU in Europe and were approved by Oxford University's central Committee on Animal Care and Ethical Review. All procedures performed in the Hubrecht Institute were approved by the Animal Welfare Body of the Royal Dutch Academy of Sciences and Arts in compliance with animal welfare laws, guidelines and policies, according to Dutch and European law. Ethical approval was also obtained from the Institutional Animal Care and Use Committees of Massachusetts General Hospital and Boston College.

Generation of transgenic zebrafish strains

To generate cardiomyocyte-specific mutants, guide shuttles carrying three gRNAs targeting either *mdh1aa* or *mdh1ab* were assembled and injected as previously described⁴⁷. In short, three gene-specific gRNAs without predicted off-targets in the zebrafish genome were selected using CRISPRscan⁵⁷ and subsequently cloned in vectors containing the *U6a*, *U6b* and *U6c* zebrafish promoters. These U6-gRNA cassettes were then subcloned and combined using Gibson Assembly into a Tol1-based construct carrying a transgenesis reporter that labels cardiomyocytes with the red fluorescent protein mKate. The resulting *pTol1-U6abc-mdh1aa-cmlc2:n-mKate* and *pTol1-U6abc-mdh1ab-cmlc2:n-mKate* plasmids were injected into *cardiodeleter* embryos at the one-cell stage with *Tol1* mRNA. Injected animals were screened at 72 hpf to select embryos showing mKate expression in cardiomyocytes, raised to adulthood and screened for transmission. F₁ animals carrying the *cardiodeleter* and corresponding guide shuttle were used for regeneration experiments. Targeted regions (including PAM) are as follows: GTTTTG-GTGACTGGCGCCGCCGG, GGGCATAGAGCCACCAAGATGG and TGTTGTGGTCCAGACGGGTCAGG for *mdh1aa* and TGCGATCTGTC-CTGCCGACCCGG, TGGCTGGGTTGCCAACACTAGG and GTGAA-GAATGTGATCATCTGGGG for *mdh1ab*.

To generate cardiomyocyte-specific overexpression models, *pTol2-cmlc2-mdh1ab-P2A-GFP-Tol2* and *pTol2-cmlc2-GFP-Tol2* were designed and ordered from VectorBuilder, transformed as previously described⁵⁸. *Escherichia coli* HST08 Stellar Competent cells (TaKaRa) were incubated for 30 minutes with 5 ng of the plasmid at 4 °C for 30 minutes. The cells were heat shocked at 42 °C for 45 seconds, cooled down for 2 minutes at 4 °C, incubated for 1 hour at 37 °C in SOC medium (TaKaRa) and plated on LB agar plates (Q-BIO gene) containing 80 µg ml⁻¹ carbenicillin (Thermo Fisher Scientific) overnight at 37 °C. Single colonies were expanded in LB broth overnight at 37 °C, and DNA was isolated using a QIAprep Spin Miniprep Kit (Qiagen) according to the manufacturer's instructions. pCS2-Tol1 and pCS-Tp-Tol2 plasmids were linearized with NotI-HF (New England Biolabs) and purified using a QIAquick PCR Purification Kit (Qiagen) according to the manufacturer's instructions. In vitro transcription of the Tol1/Tol2 genes was achieved using an mMESSAGE mACHINE SP6 Transcription Kit (Invitrogen). DNA and mRNA concentration was assessed using a NanoDrop 2000 (Thermo Fisher Scientific). Microinjection of zebrafish embryos was performed as previously described⁵⁹. Single-cell-stage zebrafish embryos were injected (FemtoJet 4x; Eppendorf) with a mix of 50 ng µl⁻¹ plasmid DNA and 50 ng µl⁻¹ Tol2 RNA. Founder embryos were bred to wild-type zebrafish to produce the F₁ generation stably expressing the transgene(s).

Cryo-injury of zebrafish and *A. mexicanus* heart

Zebrafish (5 months–1.5 years old) and *A. mexicanus* (2 years old) were used, age matched within experiments. Cryo-injury of the ventricle of zebrafish and *A. mexicanus* heart was performed per previous description⁶⁰. In brief, fish were anesthetized in MS-222 (250 mg l⁻¹; Sigma-Aldrich) and placed ventral side facing upwards in a sponge-holder under a dissection microscope (Olympus). An incision was made using forceps and microdissection scissors at the level of the heart, which facilitated the exposure of the ventricle out of the pericardial cavity. Cryo-injury was induced on the tip of the ventricle using a copper probe pre-chilled in liquid nitrogen. In sham groups, a probe at room temperature was used. After surgery, fish were returned to fresh tank water immediately, and their gills were pipetted through using water to facilitate breathing and restoring of swimming capability. Hearts were isolated at the indicated timepoints and processed for further analysis.

Heart sample fixation, processing and histology sections

Isolated hearts were rinsed in pre-cooled PBS and fixed in 4% paraformaldehyde (ChemCruz) overnight at 4 °C. Dehydration was performed using increasing ethanol concentrations (70%, 80%, 90%, 96% and 100%). After overnight incubation in 100% 1-butanol, the samples were placed in paraffin (Paraplast; Sigma-Aldrich) at 65 °C, and 8-µm-thick sections were acquired using a Microm HM325 microtome. The sections were mounted on SuperFrost glass slides (VWR) and dried overnight at 37 °C for further processing.

Acid Fuchsin Orange G staining

After sectioning the whole heart, exactly one in 10 sections was mounted per set, providing representative coverage of the whole heart for Acid Fuchsin Orange G (AFOG) staining. The procedure was performed as previously described⁶⁰. In brief, the samples were de-waxed twice for 6 minutes in Histo-Clear II (National Diagnostics), rehydrated in descending concentration of ethanol (100%, 96%, 90%, 80% and 70%, 1 minute each), fixed in Bouin's solution (Sigma-Aldrich) at 60 °C for 2 hours and stained in AFOG solution (0.5% w/v methyl blue, 1% w/v orange G and 1.5% w/v acid fuchsin (pH 1.09)) for 7 minutes. The stained slides were dehydrated in ascending concentration of ethanol (70%, 80%, 90%, 96% and 100%, 1 minute each) and washed twice for 6 minutes in Histo-Clear II. Finally, the slides were briefly allowed to dry before being mounted in dibutylphthalate polystyrene xylene (DPX) medium (Sigma-Aldrich) for imaging.

Immunofluorescence staining

For immunofluorescence analysis, we took at least three sections per heart with typical wound for further processing. The samples were de-waxed with xylene (Sigma-Aldrich) and rehydrated as described above. The sections were boiled in antigen unmasking solution, citric acid based (Vector Laboratories), for 4 minutes in a pressure cooker, followed by a cool-down period in PBS for 20 minutes. The sections were then incubated in TNB (Akoya Biosciences) blocking buffer (0.1 M Tris base (pH 7.4), 0.15 M NaCl, 0.5% TNB) for 30 minutes to 1 hour at room temperature to prevent non-specific binding. Incubation with primary antibody solution was performed in a humidified chamber at room temperature overnight. After washing with PBST (containing 0.1% Tween 20), sections were incubated with secondary antibodies for 2 hours at room temperature. Primary antibodies Mef2c (Biorbyt, orb256682), PCNA (clone PC10; Dako, M0879), GFP (Abcam, ab13970), MF20 (Developmental Studies Hybridoma Bank (DSHB), AB_2147781) and embcmhc N2.261 (DSHB, AB_531790) and secondary antibodies Alexa Fluor 488 (Invitrogen, anti-mouse A11001, anti-chick A11039 and anti-rabbit A21206) and Alexa Fluor 555 (Invitrogen, A31570) were prepared using TNB buffer at a ratio of 1:200. When the staining was ready, the sections were stained using DAPI (1:1,500 in TNB) for 5 minutes and were mounted in a self-made mounting medium, Mowiol 4-88 (AppliChem), for imaging.

RNAscope

For RNAscope, we mounted three sections per heart with typical wound for further processing. The samples were deparaffinized in xylene, incubated in 100% ethanol and air dried. After a 10-minute incubation in H₂O₂, the samples were boiled in target retrieval (Bio-Techne) for 15 minutes, washed in ethanol and allowed to dry. The *mdh1ab* (Bio-Techne, 1175851-C1) zebrafish probe was applied at 40 °C (HybEZ II oven; ACD) after a 12-minute incubation with protease III (Bio-Techne). Amp1, Amp2 and Amp3 were added before incubating in HRP-C1, TSA-fluorescein and HRP blocker at 40 °C (Bio-Techne). Two washes in RNAscope wash buffer (Bio-Techne) were performed in between each step. Immunofluorescence staining was then performed, and the slides were mounted with ProLong Gold antifade mounting medium (Invitrogen).

Drug treatment

The KCL strain was used for all inhibitor experiments. The drug solutions of PF-04859989 (Sigma-Aldrich, 0.2 µM) and rotenone (MP Bio-medicals, 5 µM) were prepared in 0.01 µM DMSO (Sigma-Aldrich) in Milli-Q water. The drugs were then injected intraperitoneally, together with a control DMSO (0.01 µM) group using a BD Micro-Fine U-100 insulin syringe (29-gauge) with injection volume of 10 µl. For the 7-dpci heart isolation, fish were injected once daily from 3 dpci to 7 dpci. For 21-dpci isolation, hearts were injected every other day between 1 dpci and 20 dpci.

Bulk RNA-seq and data analysis

Both zebrafish and *A. mexicanus* hearts were harvested at desired timepoints, and total RNA was extracted from individual ventricles using a Quick-RNA MicroPrep Kit (Zymo Research). The quality of RNA was assessed using a NanoDrop 2000 (Thermo Fisher Scientific), a Qubit RNA HS assay (Thermo Fisher Scientific) and an Agilent 2100 Bioanalyzer. We used 1.5 µg of total RNA. Libraries were generated using a QuantSeq 3' mRNA-Seq Library Prep Kit (FWD) from Lexogen. The zebrafish libraries were then sequenced using two lanes on the NovaSeq 6000 platform and those of *A. mexicanus* on the Illumina HiSeq 4000 by Oxford Genomics at the Wellcome Centre for Human Genetics. Reads were demultiplexed using bcl2fastq (version 2.20.0, Illumina) and checked for quality (adapter trimming and quality control with Trim Galore (version 0.6.4_dev))⁶¹ before alignment and gene counting using STAR (version 2.7.6a)⁶² against the zebrafish genome (GRCz11) with Ensembl (<https://ensembl.org>) annotations (release 104). For *Astyanax*, alignment was against the Mexican tetra (version 2.0) genome with customized Ensembl annotations (release 103; see GSE234989 for table)⁶³. Raw reads and gene counts are accessible under accession number GSE234990 in the Gene Expression Omnibus (GEO) repository. Gene counts were loaded in R (version 4.0.1)⁶⁴, and genes with less than one read per million mapped in all samples were removed before further analysis. Differential gene expression (DGE) was determined using DESeq2 (ref. 65) after controlling for unwanted variation with RUVg⁶⁶, using genes with a coefficient of variation less than the median as negative controls for RUVg. The weight matrix generated by RUVg was added to the linear model for DESeq2 DGE analysis. Genes were deemed to be differentially expressed if they showed more than two-fold differences at a Benjamini–Hochberg⁶⁷ adjusted $P < 0.05$. Gene Ontology enrichment was evaluated using Metascape (<http://metascape.org>) using zebrafish annotations and a background comprising genes retained for analysis²⁶. For KEGG pathway analysis^{68–70}, differential expression analysis was performed using the generalized linear models in edgeR (version 4.3.1)⁷¹. Genes with fold change > 1.5 and false discovery rate < 0.1 were extracted for enrichment analysis. The enrichment analysis was performed using EnrichR version 3.4.0 (ref. 72) on the zebrafish KEGG 2019 dataset, with default parameters. Genome-scale metabolism modeling (GEM) was performed using the continuous_integration scoring strategy in troppo version 0.0.7 (BioSystemsUM; Tissue-specific RecOnstruction and Phenotype

Prediction using Omics data; <https://github.com/BioSystemsUM/troppo>; accessed 27 February 2025) on the ZebrafishGEM model⁷³, with the raw RNA-seq counts as input. Heatmaps were produced using pheatmap⁷⁴ in R. Venn diagrams were made with R packages Vennrable (proportional Venn⁷⁵) or gplots (petal plots⁷⁶). For plots of expression pattern correlation with *acta1*, *tnnc1a* or *myl7*, genes with correlation coefficient > 0.7 across time are shown. Reanalysis of the published zebrafish bulk RNA-seq data was performed on the original dataset as published³⁸.

scRNA-seq and data processing

Transgenic zebrafish hearts at desired timepoints 1, 3 and 7 dpci were dissected, and the procedures for cardiac cell dissociation, viable sorting, transcript in vivo and sequencing follow our previous description¹³. Cells were harvested and libraries were generated by Single Cell Discoveries for 75-bp paired-end scRNA-seq using an Illumina Next-Seq platform⁷⁷. The resultant sequencing data were mapped against zebrafish reference genome (Zv9). Mitochondrial, oversequenced and ERCC spike-in mRNA reads were removed. Based on the distribution of the log₁₀ total reads plotted against frequency, we introduced a cutoff at minimally 500 reads per cell to be included for further analysis. A total of 1,194 cells (280 1-dpci, 262 3-dpci and 652 7-dpci cells) were then processed in Seurat version 3.2.2 (ref. 78) with the following parameters: variable features = 500, dimensions = 8 and resolution = 0.7. Cells that were filtered with the above parameters were subjected to pseudotime analysis using Monocle 2 (ref. 79). Monocle 2 was used to identify genes differentially expressed over pseudotime ($P < 0.05$) and identified eight unsupervised clusters. For functional annotation of the genes, zebrafish gene IDs were converted to human ensemble IDs using Ensembl biomaRt^{80,81}, and Gene Ontology term analysis was performed using DAVID⁸² and Metascape²⁶. StemID2 (ref. 83) was used on the Seurat object, and values were projected in pseudotime with Monocle 2. Reanalysis of the published zebrafish scRNA-seq datasets was performed on the original datasets as published^{13,27}.

scRNA and bulk RNA-seq data have been deposited at the GEO (Super Series GSE234990) and are publicly available as of the date of publication by accession numbers in the key resources table (Supplementary Table 21).

Seahorse assay

The Seahorse XF Cell Mito Stress Test Kit (Agilent) was used to determine the OCR and ECAR of uninjured and 14-dpci zebrafish ventricles. The ventricles were positioned in an Islet Capture Microplate (Agilent, 101122-100) containing DMEM (Agilent, 1035755-100; 10 mM glucose, 1 mM pyruvate and 2 mM glutamine (pH 7.4)). Ten baseline (untreated), three oligomycin (MP Biochemicals) (50 µM), seven FCCP (Sigma-Aldrich) (30 µM) and nine rotenone (MP Biochemicals)/antimycin A (ChemCruz) (45 µM) measurements were acquired using the Seahorse XFe24 Analyzer (Agilent) at 28 °C. Seahorse traces were normalized against protein concentration using a Pierce BCA Assay Kit (Thermo Fisher Scientific). The OCR was defined as the average of the top three FCCP measurements.

¹³C metabolic analysis by nuclear magnetic resonance

To evaluate how glucose is metabolized, we injected 4 M ¹³C₆ glucose (ChemCruz) in Milli-Q water intraperitoneally in wild-type zebrafish from the KCL strain at 7 dpci and then isolated and snap-froze the hearts 30 minutes after injection. To extract the metabolites, three replicates of 10 pooled ventricles were homogenized in 1 ml of pre-chilled 2:1 chloroform (Thermo Fisher Scientific): methanol (Sigma-Aldrich) extraction solution in a homogenizer (hard tissue grinding MK28; Precellys). The lysate was subsequently placed at 4 °C for 5 minutes before adding 400 µl of Milli-Q water, mixing thoroughly and centrifuging at 10,000g for 5 minutes at 4 °C. The aqueous phase containing the metabolites was isolated, freeze dried, reconstituted in deuterium

oxide (D₂O) and analyzed quantitatively using nuclear magnetic resonance (NMR) spectroscopy.

All NMR experiments were performed on a Bruker Avance NEO NMR spectrometer operating at a proton resonance frequency of 600 MHz and equipped with a BBO CryoProbe. Measurements were done at a temperature of 298 K. Data were acquired using the TopSpin 4.1.4 software package and analyzed using MestReNova (Mestrelab Research). Spectral annotations were performed according to the literature⁸⁴.

Scanning electron microscopy

Adult zebrafish WIK and SAT 7-dpci hearts were isolated and fixed at room temperature with a mixture of 2.5% glutaraldehyde/2% paraformaldehyde in 0.1 M sodium cacodylate buffer (pH 7.4). Hearts were then washed in 0.1 M PIPES (Thermo Fisher Scientific) and fixed with osmium tetroxide (2%) (Agar Scientific) and potassium ferricyanide (1.5%) (Merck) for 2 hours. After washing in buffer, the samples were treated with tannic acid followed by 2% osmium tetroxide and 1% uranyl acetate (Agar Scientific), respectively. After heavy metal staining, the samples were dehydrated through ethanol series, acetone and Durcupan/acetone gradient and embedded in Durcupan ACM resin (Sigma-Aldrich). Semi-thin sections were cut at 500 nm with a Leica Ultracut 7 ultramicrotome and mounted on a glass coverslip for counterstaining with lead citrate. Coverslips were finally mounted on stubs with conductive carbon adhesive tabs, and the heart tissue was coated with carbon (Quorum Technologies) for imaging.

Imaging

Whole zebrafish images were taken using an iPhone X (Apple). Whole hearts were imaged with a Zeiss Stemi 2000-C stereomicroscope with a Zeiss Axiocam ERC5s camera (Carl Zeiss). (Immuno)histochemistry images of heart samples were acquired using a Nikon Eclipse Ci-L microscope with a Nikon DS-Fi3 camera and a Zeiss LSM 800 (Carl Zeiss). The scanning electron microscopy images were acquired at 10 kV with detector HDBSD (working distance 5.9 mm) using Zeiss Sigma 300 FEG-SEM.

Quantification of stained sections

We used Fiji ImageJ software (<https://imagej.net/Fiji>)⁸⁵ to quantify wound size and cellular foci of images. For AFOG-stained sections, we quantified wound size, including area and open wound length, on a minimum of three sections per heart with the largest wound. The wound size was presented as a percentage of wound area and length against the ventricular area and perimeter, respectively. Additionally, to characterize the regenerative state at 90 dpci, the hearts were visually categorized into three groups: (1) completely regenerated (total lack of wound throughout the heart), (2) incompletely regenerated with closed wound (only internal collagenous scar present) and (3) incompletely regenerated with open wound (absence of compact wall closure and/or fibrin deposition additionally to collagen deposits). The percentage of hearts in each category is presented per strain.

For proliferation measurements, we counted Mef2⁺PCNA⁺ double-labeled nuclei and those labeled only by Mef2⁺ or PCNA⁺MF20⁺ cells within the border zone, a 100-μm region adjacent to the wound border. The percentage of proliferating cardiomyocytes was obtained by dividing the number of PCNA⁺Mef2⁺ against the total Mef2⁺ nuclei or PCNA⁺ nuclei over the border zone area (pxl²). For embryonic myosin, we identified embcmhc signal in the border zone and normalized by inner wound length.

Amira software (Thermo Fisher Scientific) was used to quantify the area of the compact wall, trabecular muscle⁸⁶ and atrium of the uninjured hearts. To correct for variation in atrium size due to differences in the size of the hearts, the atrial area was corrected by the total area of the heart.

Statistics

Data analysis was performed blinded, and the data were plotted using GraphPad Prism version 9.1.0 (GraphPad Software). Animal numbers in each experiment and details on statistical tests are included in the figures or their legends. Data are presented as mean ± s.e.m. The box in the box plots indicates the 25th and 75th percentiles and the middle line the 50th percentile. The whiskers extend to the most extreme data points.

Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Data availability

The RNA-seq datasets generated in this study are deposited in the GEO repository under a SuperSeries with accession number [GSE234990](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE234990) (wild-type strains bulk RNA-seq: [GSE234990](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE234990); *Astyanax* bulk RNA-seq: [GSE234989](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE234989); scRNA-seq: [GSE237276](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE237276)). Published datasets reanalyzed in this study come from the following studies: Hu et al.²⁷ ([GSE159032](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE159032)), Honkoop et al.¹³ ([GSE139218](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE139218)) and Hill et al.³⁸ ([SRP117696](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=SRP117696)). The raw data/measurements presented in this study are provided in the Source Data table. The materials used in this study are provided in the key resources table (Supplementary Table 21). Any further queries may be directed to the corresponding author, M.T.M.M. (mathilda.mommersteeg@dpag.ox.ac.uk). Source data are provided with this paper.

Code availability

The code used to analyze the datasets is commercially available and is described and referenced in the Methods. Custom code relating to Extended Data Fig. 3 can be found at https://github.com/JasonJunYing/Oxphos_regeneration.

References

- Poss, K. D., Wilson, L. G. & Keating, M. T. Heart regeneration in zebrafish. *Science* **298**, 2188–2190 (2002).
- Garbern, J. C. & Lee, R. T. Heart regeneration: 20 years of progress and renewed optimism. *Dev. Cell* **57**, 424–439 (2022).
- Bae, J., Paltzer, W. G. & Mahmoud, A. I. The role of metabolism in heart failure and regeneration. *Front. Cardiovasc. Med.* **8**, 702920 (2021).
- Stanley, W. W. C., Recchia, F. A. & Lopaschuk, G. D. Myocardial substrate metabolism in the normal and failing heart. *Physiol. Rev.* **85**, 1093–1129 (2005).
- Mills, R. J. et al. Functional screening in human cardiac organoids reveals a metabolic mechanism for cardiomyocyte cell cycle arrest. *Proc. Natl Acad. Sci. USA* **114**, E8372–E8381 (2017).
- Porrello, E. R. et al. Transient regenerative potential of the neonatal mouse heart. *Science* **331**, 1078–1080 (2011).
- Puente, B. N. et al. The oxygen-rich postnatal environment induces cardiomyocyte cell-cycle arrest through DNA damage response. *Cell* **157**, 565–579 (2014).
- Hirose, K. et al. Evidence for hormonal control of heart regenerative capacity during endothermy acquisition. *Science* **188**, eaar2038 (2019).
- Derks, W. & Bergmann, O. Polyploidy in cardiomyocytes: roadblock to heart regeneration? *Circ. Res.* **126**, 552–565 (2020).
- Hu, N., Joseph Yost, H. & Clark, E. B. Cardiac morphology and blood pressure in the adult zebrafish. *Anat. Rec.* **264**, 1–12 (2001).
- Beisaw, A. & Wu, C. C. Cardiomyocyte maturation and its reversal during cardiac regeneration. *Dev. Dyn.* **253**, 8–27 (2022).
- Mortimer, C. H. The oxygen content of air-saturated fresh waters, and aids in calculating percentage saturation. *SIL Communications*, 1953–1996 <https://doi.org/10.1080/05384680.1956.11904088> (1956).

13. Honkoop, H. et al. Single-cell analysis uncovers that metabolic reprogramming by ErbB2 signaling is essential for cardiomyocyte proliferation in the regenerating heart. *Elife* **8**, e50163 (2019).
14. Fukuda, R. et al. Stimulation of glycolysis promotes cardiomyocyte proliferation after injury in adult zebrafish. *EMBO Rep.* **21**, 1–13 (2020).
15. Miklas, J. W. et al. Amino acid primed mTOR activity is essential for heart regeneration. *iScience* **25**, 103574 (2022).
16. Spelat, R. et al. Metabolic reprogramming and membrane glycan remodeling as potential drivers of zebrafish heart regeneration. *Commun. Biol.* **5**, 1365 (2022).
17. Li, L. et al. An organ-wide spatiotemporal transcriptomic and cellular atlas of the regenerating zebrafish heart. *Nat. Commun.* **16**, 3716 (2025).
18. Sallin, P., de Preux Charles, A. S., Duruz, V., Pfefferli, C. & Jazwińska, A. A dual epimorphic and compensatory mode of heart regeneration in zebrafish. *Dev. Biol.* **399**, 27–40 (2015).
19. Bise, T., Sallin, P., Pfefferli, C. & Jazwińska, A. Multiple cryoinjuries modulate the efficiency of zebrafish heart regeneration. *Sci. Rep.* **10**, 11551 (2020).
20. Chablais, F., Veit, J., Rainer, G. & Jazwinska, A. The zebrafish heart regenerates after cryoinjury-induced myocardial infarction. *BMC Dev. Biol.* **11**, 21 (2011).
21. Reuter, H. et al. Aging activates the immune system and alters the regenerative capacity in the zebrafish heart. *Cells* **11**, 345 (2022).
22. Hein, S. J. et al. Advanced echocardiography in adult zebrafish reveals delayed recovery of heart function after myocardial cryoinjury. *PLoS ONE* **10**, e0122665 (2015).
23. Bednarek, D. et al. Telomerase is essential for zebrafish heart regeneration. *Cell Rep.* **12**, 1691–1704 (2015).
24. Lowe, V. et al. Neuropilin 1 mediates epicardial activation and revascularization in the regenerating zebrafish heart. *Development* **146**, dev174482 (2019).
25. González-Rosa, J. M., Martín, V., Peralta, M., Torres, M. & Mercader, N. Extensive scar formation and regression during heart regeneration after cryoinjury in zebrafish. *Development* **138**, 1663–1674 (2011).
26. Zhou, Y. et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. *Nat. Commun.* **10**, 1523 (2019).
27. Hu, B. et al. Origin and function of activated fibroblast states during zebrafish heart regeneration. *Nat. Genet.* **54**, 1227–1237 (2022).
28. Li, X. et al. Mitochondrial dysfunction in fibrotic diseases. *Cell Death Discov.* **6**, 80 (2020).
29. Borst, P. The malate–aspartate shuttle (Borst cycle): how it started and developed into a major metabolic pathway. *IUBMB Life* **72**, 2241–2259 (2020).
30. Yoshida, T. et al. A covalent small molecule inhibitor of glutamate-oxaloacetate transaminase 1 impairs pancreatic cancer growth. *Biochem. Biophys. Res. Commun.* **522**, 633–638 (2020).
31. Bertozzi, A. et al. Is zebrafish heart regeneration ‘complete’? Lineage-restricted cardiomyocytes proliferate to pre-injury numbers but some fail to differentiate in fibrotic hearts. *Dev. Biol.* **471**, 106–118 (2021).
32. Funakoshi, S. et al. Generation of mature compact ventricular cardiomyocytes from human pluripotent stem cells. *Nat. Commun.* **12**, 3155 (2021).
33. Jopling, C. et al. Zebrafish heart regeneration occurs by cardiomyocyte dedifferentiation and proliferation. *Nature* **464**, 606–609 (2010).
34. Nguyen, P. D. et al. Interplay between calcium and sarcomeres directs cardiomyocyte maturation during regeneration. *Science* **380**, 758–764 (2023).
35. Tsedek, A. T. et al. Cardiomyocyte heterogeneity during zebrafish development and regeneration. *Dev. Biol.* **476**, 259–271 (2021).
36. Fukuda, R. et al. Metabolic modulation regulates cardiac wall morphogenesis in zebrafish. *eLife* **8**, e50161 (2019).
37. Lopaschuk, G. D., Collins-Nakai, R. L. & Itoi, T. Developmental changes in energy substrate use by the heart. *Cardiovasc. Res.* **26**, 1172–1180 (1992).
38. Hill, J. T., Demarest, B., Gorski, B., Smith, M. & Yost, H. J. Heart morphogenesis gene regulatory networks revealed by temporal expression analysis. *Development* **144**, 3487–3498 (2017).
39. Kuzniak-Glancy, S., Glancy, B. & Kay, M. W. Ischemic damage to every segment of the oxidative phosphorylation cascade elevates ETC driving force and ROS production in cardiac mitochondria. *Am. J. Physiol. Heart Circ. Physiol.* **323**, H499–H512 (2022).
40. Terrand, J., Papageorgiou, I., Rosenblatt-Velin, N. & Lerch, R. Calcium-mediated activation of pyruvate dehydrogenase in severely injured postischemic myocardium. *Am. J. Physiol. Heart Circ. Physiol.* **281**, H722–H730 (2001).
41. Ben-Yair, R. et al. H3K27me3-mediated silencing of structural genes is required for zebrafish heart regeneration. *Development* **146**, dev178632 (2019).
42. Itou, J. et al. Migration of cardiomyocytes is essential for heart regeneration in zebrafish. *Development* **139**, 4133–4142 (2012).
43. Beisaw, A. et al. AP-1 contributes to chromatin accessibility to promote sarcomere disassembly and cardiomyocyte protrusion during zebrafish heart regeneration. *Circ. Res.* **126**, 1760–1778 (2020).
44. Morikawa, Y. et al. Actin cytoskeletal remodeling with protrusion formation is essential for heart regeneration in Hippo-deficient mice. *Sci. Signal.* **8**, ra41 (2015).
45. Yoshida, Y. et al. Selective and competitive inhibition of kynurenine aminotransferase 2 by glycyrrhizic acid and its analogues. *Sci. Rep.* **9**, 10243 (2019).
46. Li, N. et al. Mitochondrial complex I inhibitor rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production. *J. Biol. Chem.* **278**, 8516–8525 (2003).
47. Keeley, S. et al. Rapid and robust generation of cardiomyocyte-specific *crisprants* in zebrafish using the *cardiodeleter* system. *Cell Rep. Methods* **5**, 101003 (2025).
48. Stockdale, W. T. et al. Heart regeneration in the Mexican cavefish. *Cell Rep.* **25**, 1997–2007 (2018).
49. Potts, H. G., Stockdale, W. T. & Mommersteeg, M. T. M. Unlocking the secrets of the regenerating fish heart: comparing regenerative models to shed light on successful regeneration. *J. Cardiovasc. Dev. Dis.* **8**, 4 (2021).
50. Stewart, K. M. R., Walker, S. L., Baker, A. H., Riley, P. R. & Brittan, M. Hooked on heart regeneration: the zebrafish guide to recovery. *Cardiovasc. Res.* **118**, 1667–1679 (2022).
51. García-Poyatos, C. et al. Cox7a1 controls skeletal muscle physiology and heart regeneration through complex IV dimerization. *Dev. Cell* **59**, 1824–1841 (2024).
52. Guo, Y. & Pu, W. T. Cardiomyocyte maturation: new phase in development. *Circ. Res.* **126**, 1086–1106 (2020).
53. Shakked, A. et al. Redifferentiated cardiomyocytes retain residual dedifferentiation signatures and are protected against ischemic injury. *Nat. Cardiovasc. Res.* **2**, 383–398 (2023).
54. Dimasi, C. G., Darby, J. R. T. & Morrison, J. L. A change of heart: understanding the mechanisms regulating cardiac proliferation and metabolism before and after birth. *J. Physiol.* **601**, 1319–1341 (2023).
55. Cantó, C., Menzies, K. J. & Auwerx, J. NAD⁺ metabolism and the control of energy homeostasis: a balancing act between mitochondria and the nucleus. *Cell Metab.* **22**, 31–53 (2015).

56. Aleström, P. et al. Zebrafish: housing and husbandry recommendations. *Lab Anim.* **54**, 213–224 (2020).
57. Moreno-Mateos, M. A. et al. CRISPRscan: designing highly efficient sgRNAs for CRISPR–Cas9 targeting in vivo. *Nat. Methods* **12**, 982–988 (2015).
58. Lekkos, K. et al. Validation of positional candidates *Rps6ka6* and *Pou3f4* for a locus associated with skeletal muscle mass variability. *G3 (Bethesda)* **14**, jkae046 (2024).
59. Rosen, J. N., Sweeney, M. F. & Mably, J. D. Microinjection of zebrafish embryos to analyze gene function. *J. Vis. Exp.* **1115** (2009).
60. Koth, J. et al. Runx1 promotes scar deposition and inhibits myocardial proliferation and survival during zebrafish heart regeneration. *Development* **147**, dev186569 (2020).
61. Krueger, F. Trim Galore. *Babraham Bioinformatics* https://www.bioinformatics.babraham.ac.uk/projects/trim_galore (2019).
62. Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* **29**, 15–21 (2013).
63. Potts, H. G. et al. Discordant genome assemblies drastically alter the interpretation of single-cell RNA sequencing data which can be mitigated by a novel integration method. *Cells* **11**, 608 (2022).
64. R Core Team R: A Language and Environment for Statistical Computing (R Core Team, 2015).
65. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.* **15**, 550 (2014).
66. Risso, D., Ngai, J., Speed, T. P. & Dudoit, S. Normalization of RNA-seq data using factor analysis of control genes or samples (RUVSeq). *Nat. Biotechnol.* **32**, 896–902 (2014).
67. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J. R. Stat. Soc. Series B Stat. Methodol.* **57**, 289–300 (1995).
68. Kanehisa, M. & Goto, S. KEGG: Kyoto Encyclopedia of Genes and Genomes. *Nucleic Acids Res.* **28**, 27–30 (2000).
69. Kanehisa, M. Toward understanding the origin and evolution of cellular organisms. *Protein Sci.* **28**, 1947–1951 (2019).
70. Kanehisa, M., Furumichi, M., Sato, Y., Matsuura, Y. & Ishiguro-Watanabe, M. KEGG: biological systems database as a model of the real world. *Nucleic Acids Res.* **53**, D672–D677 (2025).
71. Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics* **26**, 139–140 (2009).
72. Chen, E. Y. et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. *BMC Bioinformatics* **14**, 128 (2013).
73. Wang, H. et al. Genome-scale metabolic network reconstruction of model animals as a platform for translational research. *Proc. Natl Acad. Sci. USA* **118**, e2102344118 (2025).
74. Kolde, R. pheatmap: Pretty Heatmaps. R package version 1.0.13 <https://CRAN.R-project.org/package=pheatmap> (2025).
75. Swinton, J. Vennrable: Venn and Euler area-proportional diagrams. *GitHub* <https://github.com/js229/Vennrable> (2016).
76. Warnes, G. R. et al. gplots: Various R programming tools for plotting data <https://cran.r-project.org/web/packages/gplots/gplots.pdf> (2025).
77. Muraro, M. J. et al. A single-cell transcriptome atlas of the human pancreas. *Cell Syst.* **3**, 385–394 (2016).
78. Stuart, T. et al. Comprehensive integration of single-cell data. *Cell* **177**, 1888–1902. (2019).
79. Qiu, X. et al. Reversed graph embedding resolves complex single-cell trajectories. *Nat. Methods* **14**, 979–982 (2017).
80. Durinck, S. et al. BioMart and Bioconductor: a powerful link between biological databases and microarray data analysis. *Bioinformatics* **21**, 3439–3440 (2005).
81. Durinck, S., Spellman, P. T., Birney, E. & Huber, W. Mapping identifiers for the integration of genomic datasets with the R/ Bioconductor package biomaRt. *Nat. Protoc.* **4**, 1184–1191 (2009).
82. Sherman, B. T. et al. DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update). *Nucleic Acids Res.* **50**, W216–W221 (2022).
83. Herman, J. S., Sagar & Grün, D. FateID infers cell fate bias in multipotent progenitors from single-cell RNA-seq data. *Nat. Methods* **15**, 379–386 (2018).
84. Hall, J. L., Gibbons, G. H. & Chatham, J. C. IGF-I promotes a shift in metabolic flux in vascular smooth muscle cells. *Am. J. Physiol. Endocrinol. Metab.* **283**, E465–E471 (2002).
85. Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. *Nat. Methods* **9**, 676–682 (2012).
86. Tang, J. L. Y. et al. The developmental origin of heart size and shape differences in *Astyanax mexicanus* populations. *Dev. Biol.* **441**, 272–284 (2018).

Acknowledgements

We would like to thank P. Riley (University of Oxford, Institute of Developmental and Regenerative Medicine) for critical reading of the manuscript as well as the staff from our animal facility at Level 1 (University of Oxford, Biomedical Services) and at the Institute of Developmental and Regenerative Medicine (University of Oxford). We would also like to acknowledge J. Postlethwait (University of Oregon, College of Arts and Sciences) for providing us with the NA strain; J. McCullagh (University of Oxford, Department of Chemistry) and J. Walsby-Tickle (University of Oxford, Department of Chemistry) for access to the Seahorse Analyzer; H. Mackenzie (University of Oxford, Department of Chemistry) for the NMR spectroscopy; and S. Nornes (University of Oxford, Institute of Developmental and Regenerative Medicine) for providing us with the pCS-Tp-Tol2 plasmid. This work was supported by the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (715895, CAVEHEART, ERC-2016-STG to M.T.M.M.); British Heart Foundation project grants (PG/15/111/31939 and PG/23/11189 to M.T.M.M.); EMBO Long Term Fellowship (ALTF1129-2015 to P.D.N.); HFSP Fellowship (LTO01404/2017-L to P.D.N.); NWO-ZonMW Veni grant (016.186.017-3 to P.D.N.); Medical Research Council (MR/W006731/1 to K.L. and MR/N013468/1 to E.S.); Clarendon Fund (to E.S.); King Faisal Specialist Hospital & Research Centre (postdoctoral fellowship to R.A.); British Heart Foundation PhD program (FS/17/68/33478 to H.G.P.); British Heart Foundation IBSRF (FS/17/58/33072 to L.C.H.); German Center for Cardiovascular Research (81Z0100103 to D.P.); Helmholtz Association (ERC-RA-0047 to D.P.); National Natural Science Foundation of China (82100465 to X.W.); American Heart Association (19CDA34660207 to J.M.G.-R.); National Institutes of Health (R01HL164749 to J.M.G.-R.); ERC-CoG HEART_STATES (101043364 to J.P.J.); and Dutch Heart Foundation and Hartekind (CVON2019-002 OUTREACH and ERA-CVD-2016T088 CARDIO-PRO to J.B.). M.T.M.M. acknowledges support from the British Heart Foundation Oxford Centre of Research Excellence, University of Oxford (RE/24/130024), and the British Heart Foundation Centre of Regenerative Medicine (RM/13/3/30159).

Author contributions

Conceptualization: M.T.M.M. Investigation: K.L., Z.H., P.D.N., H.H., E.S., R.A., J.K., J.Y., M.E.L., A.K., S.K., B.S., B.W.C.K., X.S., K.B., H.G.P., G.R., J.M. and J.M.G.-R. Funding acquisition: M.T.M.M. Supervision: M.T.M.M., Z.H., K.L., D.P., J.P.J., L.C.H., X.W., J.M.G.-R. and J.B. Writing—original draft: K.L., Z.H. and M.T.M.M. Writing—review and editing: all authors.

Competing interests

The authors declare no competing interests.

Additional information

Extended data is available for this paper at <https://doi.org/10.1038/s44161-025-00718-x>.

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s44161-025-00718-x>.

Correspondence and requests for materials should be addressed to Mathilda T. M. Mommersteeg.

Peer review information *Nature Cardiovascular Research* thanks the anonymous reviewer(s) for their contribution to the peer review of this work.


Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2025


¹Institute of Developmental and Regenerative Medicine, University of Oxford, Oxford, UK. ²Department of Physiology, Anatomy & Genetics, University of Oxford, Oxford, UK. ³Hubrecht Institute-KNAW and University Medical Center Utrecht, Utrecht, The Netherlands. ⁴Institut Curie, PSL University, Sorbonne Université, CNRS UMR3215, Inserm U934, Genetics and Developmental Biology, Paris, France. ⁵King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia. ⁶MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, UK. ⁷Faculty of Medical Laboratory Science, College of Health Science and Technology, Shanghai Jiao Tong University School of Medicine, Shanghai, China. ⁸Bioinfo, Plantagenet, Ontario, Canada. ⁹Department of Biology, Morrissey College of Arts and Sciences, Boston College, Chestnut Hill, MA, USA. ¹⁰Max Delbrück Center for Molecular Medicine, Berlin, Germany. ¹¹Charité – Universitätsmedizin Berlin, Berlin, Germany. ¹²Department of Chemistry, University of Oxford, Oxford, UK. ¹³DZHK (German Centre for Cardiovascular Research) partner site, Berlin, Germany. ¹⁴Department of Congenital Heart Disease and Pediatric Cardiology, University Hospital Schleswig-Holstein, Kiel, Germany. ¹⁵School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China. ¹⁶Cardiovascular Research Center, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA, USA. ¹⁷Department of Pediatric Cardiology, Division of Pediatrics, University Medical Center Utrecht, Utrecht, The Netherlands. ✉ e-mail: mathilda.mommersteeg@dpag.ox.ac.uk



Extended Data Fig. 1 | Differential regenerative response to cryoinjury


between wild-type adult zebrafish strains. (a) Ratio of ventricular compact wall area and trabecular area as indication of sponginess of the hearts showing differences trabeculae between adult NA and KCL but not between other strains. (b) Quantification of atrial size showing no differences between the strains. (c) Survival curve until 90dpci showing differences in survival between the strains. (d) Survival curve until 7 days post sham. (e-f) Quantification of wound area (e) and length (f) over time in all the strains (only significant p-value between adjacent time points per strain is shown). (g) Wound length quantification showing significant differences at 1 and 90dpci between the strains. (h) No correlation between 1dpci wound length and 90dpci wound length. (i-j) Positive correlation between 7- and 21dpci (i) and 21- and 90dpci wound area (j). (k) No correlation between extend of injury (1dpci wound length) and survival. (l) No correlation between long-term regeneration (90dpci wound area) and survival. a, AB n=5; NA, KCL n=7; SAT, WIK n=6; TL n=9; TU n=4 (biological replicates);

b, AB n=5; NA, SAT, WIK n=6; TL n=9; TU n=4; KCL n=7 (biological replicates); c, AB n=42, NA n=46, SAT n=38, TL n=52, TU n=35, WIK n=34, KCL n=32 (biological replicates); d, n=5 biological replicates per strain; e, AB: 1, 90dpci n=7; 7dpci n=8; 21dpci n=6. NA: 1, 7, 90dpci n=7; 21dpci n=11. SAT: 1, 7, 21, 90dpci n=7. TL: 1, 7, 90dpci n=7; 21dpci n=9. TU: 1, 7dpci n=7; 21dpci n=5; 90dpci n=6. WIK: 1, 7, 21, 90dpci n=7. KCL: 1, 7, 21, 90dpci n=8 (biological replicates); f, AB: 1, 90dpci n=7; 7dpci n=8; 21dpci n=6. NA: 1, 7, 90dpci n=7; 21dpci n=11. SAT: 1, 7, 21, 90dpci n=7. TL: 1, 7, 90dpci n=7; 21dpci n=9. TU: 1, 7dpci n=7; 21dpci n=5; 90dpci n=6. WIK: 1, 7, 21, 90dpci n=7. KCL: 1, 7, 21, 90dpci n=8 (biological replicates); g, 1dpci: AB, NA, SAT, TL, TU, WIK n=7; KCL n=8. 7dpci: NA, SAT, TL, TU, WIK n=7; AB, KCL n=8. 21dpci: SAT, WIK n=7; AB n=6; NA n=11; TL n=9; TU n=5; KCL n=8. 90dpci: AB, NA, SAT, TL, WIK n=7; TU n=6; KCL n=8 (biological replicates). a, b, g, one-way ANOVA with Tukey's test; c, d, Kaplan-Meier assay with Log-rank (Mantel-Cox) test; e, f, two-way ANOVA with Šidák's multiple test; h-l, simple linear regression.



Extended Data Fig. 2 | Oxidative phosphorylation is beneficial for regeneration. (a) Negative correlation between 90dpi wound area and the 7dpi Respiratory electron transport GO-term. (b) Oxygen consumption rate (OCR) measurements of uninjured ventricles show similar levels of OXPHOS among the seven wild-type zebrafish strains. (c) Negative correlation between 7dpi wound length and 7dpi Glycolysis. (d) Significant positive correlation between Glycolysis and OXPHOS at 7dpi. (e) Extracellular acidification rate (ECAR) of 14dpi ventricles show significant differences in glycolysis among the seven wild-type zebrafish strains. (f) Extracellular acidification rate (ECAR) measurements of uninjured ventricles show similar levels of glycolysis among the seven wild-type zebrafish strains. (g) Nuclear magnetic resonance (NMR) analysis of ^{13}C -glucose labelled 7dpi KCL hearts identified glutamate, aspartate


and lactate as metabolites (representative spectrum and zoomed-in panels in black boxes, additional biological replicas in green and magenta boxes, total number of replicas $n=3$ containing 10 pooled hearts each). (h) Schematic of NMR traced $[U-^{13}C_6]$ -glucose being converted into lactate or entering the tricarboxylic acid (TCA) cycle via pyruvate to generate glutamate and aspartate. **b, f**, AB, SAT, TU, WIK $n=5$; NA $n=4$; TL $n=7$; KCL $n=9$ (biological replicates); **e**, $n=5$ biological replicates per strain; **g**, $n=3$ replicates containing 10 pooled hearts each. **a, c-d**, simple linear regression; **b, e-f**, one-way ANOVA with Tukey's test. RET, Respiratory Electron Transport chain; Rotenone, as used in Fig. 2c, inhibits OXPHOS through its action on Complex I; C2-4, indicates the number of the carbon labelled by ^{13}C ; CI-CV, complex I-V.



Extended Data Fig. 3 | See next page for caption.


Extended Data Fig. 3 | Activation of the Malate Aspartate Shuttle drives OXPHOS and regeneration. (a) Increased wound area in KCL treated with rotenone in comparison with DMSO control at 21dpci. (b) Representative scanning electron microscope images displaying mitochondrial morphology in the border zone versus remote zone cardiomyocytes in WIK and SAT strains at 7dpci. Arrow heads point to different morphology of border zone mitochondria between WIK and SAT. Scale bar 2µm. (c) Heatmap of top 10 genes expressed at 7dpci in the RNAseq negatively correlating to 90dpci wound length, with *mdh1ab* as top gene. (d) Negative correlation of 7dpci *mdh1ab* expression to wound length at 90dpci. (e) Violin plots showing high *mdh1ab* gene expression in cardiomyocytes compared to other cell types in re-analysed scRNAseq data of AB/TL strains at 3-, 7- and 30dpci as well as uninjured hearts. (f) Schematic diagram showing the malate aspartate shuttle (MAS) in relation to glycolysis,

the TCA cycle and OXPHOS with inhibitors used in red letters. (g) KEGG pathway enrichment analysis of the upregulated genes in NA 7dpci compared to SAT 7dpci, with fold change (FC) > 1.5 and false discovery rate (FDR) < 0.1. (h) Reaction enrichment scores of metabolic pathways within the TCA subset of the zebrafish genome-scale metabolism model (GEM). (i) Wound area quantification showing increased 21dpci wound area in KCL hearts treated with inhibitor PF-04859989 in comparison to DMSO control. **a**, rotenone n=4, DMSO n=6 (biological replicates); **i**, n=5 biological replicates per group. **a**, unpaired two-tailed Student's t-test; **c-d**, simple linear regression; **g**, Fisher exact test with Benjamini-Hochberg method for multiple hypotheses testing; **h** scaled enrichment score calculated from raw gene expression counts by troppa, with default parameters; **i**, unpaired two-tailed Welch t-test.




Extended Data Fig. 4 | OXPHOS is not required for cardiomyocyte proliferation. (a-b) No correlation between 7dpci border zone proliferation and 90dpci wound length in all strains (a) or those excluding WIK (b). (c) The top 5 enriched processes in the genes positively correlating to 7dpci border zone proliferation in the 7dpci bulk RNAseq. (d) No correlation between 7dpci cell cycle genes and 90dpci wound length. (e) Representative AFOS

images of cryo-injured hearts at 90dpci to indicate classification (Scale bar: 300μm). d, measurements of those two parameters result from two independent experiments that were performed once (the data results from different timepoints and techniques and is not paired, consequently the average measurements per characteristic have been used). a-b, d, simple linear regression; c, analysis performed using Metascape.



Extended Data Fig. 5 | Cardiomyocyte proliferation is separated in time from OXPHOS and cardiomyocyte re-differentiation. (a) Heatmap of 7dpci border zone upregulated OXPHOS genes over time in the developing heart (re-analysed from Hill et al.).39 Re-analysed bulk RNAseq eight time points from 30 to 72hpf. (b-c) Violin plots showing the higher expression level of *tnni1a* (b) and *acta1a* (c) in border zone (clusters 4 and 7) compared to remote zone cardiomyocytes (clusters 1 and 2) by re-analysis of our previous scRNAseq data. Cluster numbers


as in original publication (Honkoop et al.). (d) UMAP plot showing the border zone cardiomyocytes grouped into seven clusters. (e) UMAP plot showing the distribution of the three time points. (f) Bar chart showing the temporal cluster contributions. (g) UMAP plot of cardiomyocyte specific genes *myl7* and *tnnt2a*. (h) UMAP plot of border zone cardiomyocyte specific genes *nppa* and *mustn1b*. (i) UMAP plot of proliferation marker *pcna*. d-i, n=4 hearts per timepoint. CI, cluster.



Extended Data Fig. 6 | See next page for caption.



Extended Data Fig. 6 | OXPHOS levels follow differentiation state of the cardiomyocytes. Bulk RNAseq data of the seven wild-type zebrafish strains, plotted against the eight pseudotime modules and the six processes of interest. All samples included (uninjured, 1- and 7dpi) and visible as separate dots coloured by strain. The significantly expressed genes per pseudotime module in the scRNAseq were identified in the bulk RNAseq, averaged per sample and plotted against the processes/genes of interest. This showed an increasing positive correlation of pcna and entropy in modules 1-3, before levelling off in module 4 and switching into a negative correlation in modules 5-8. The increasing positive correlation of entropy, which is a read out of de-differentiation, within modules 1-3 indicates that the cells increase their entropy/de-differentiate in these modules. The concurrent increasing positive correlation of pcna indicates that during this time, the cardiomyocytes initiate proliferation. Reversing of the correlations in modules 5-7 indicates that

proliferation reduces and re-differentiation is initiated. There is no correlation of Glycolysis with modules 1-4, but a weak correlation with modules 5-7, indicating that Glycolysis is not associated specifically with the modules and is active throughout, albeit with a slightly stronger association to the later time points. OXPHOS and embryonic border zone marker *tnnc1a* showed an absent or weak negative correlation to modules 1-3, indicating these genes are not specifically associated with the de-differentiation and proliferation phase before switching into a positive correlation in modules 5-8. This indicates that OXPHOS and embryonic sarcomere border zone expression is specifically associated with the re-differentiation phase. Mature cardiomyocyte marker *myl7* correlates strongly negatively to modules 1-3, confirming these modules represent the de-differentiation phase, before levelling off and switching into a strong positive correlation in modules 5-7 confirming this to be the re-differentiation phase. Simple linear regression.



Extended Data Fig. 7 | Genetic manipulation of *mdh1ab* has no effect on cardiomyocyte proliferation. (a) Representative images of immunofluorescence staining of *mdh1ab* cKO and cardiodeleter 21dpci hearts labelling PCNA-positive proliferating cells and GFP-positive myocardium.

(b) Representative images of immunofluorescence staining of *mdh1ab* cOE and GFP cOE 21dpci hearts labelling PCNA-positive proliferating cells and GFP-positive myocardium. Scalebars: 100μm.



Extended Data Fig. 8 | See next page for caption.

Extended Data Fig. 8 | Strongly reduced re-differentiation gene expression in *Astyanax mexicanus* cavefish versus surface fish. (a) Representative AFOG images displaying the scarring wound in *Astyanax mexicanus* Pachon cavefish compared to the regenerating surface fish heart at 100dpci (scale bar: 100µm). (b) Quantification of wound area, showing significant difference in wound size between surface fish and Pachon cavefish. (c) Heatmap comparing all time points

in both cavefish and surface fish showing upregulated terms including TCA cycle and respiratory electron transport among the top terms in surface fish at late time point after cryoinjury. (d) Same as Fig. 7n, but with all genes annotated in heatmap. **b**, Surface fish n=6; Cavefish n=5, (biological replicates); **b** unpaired one-tailed Welch t-test; **c**, analysis performed using Metascape.

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

- | | |
|-------------------------------------|--|
| n/a | Confirmed |
| ☐ | ☒ The exact sample size (<i>n</i>) for each experimental group/condition, given as a discrete number and unit of measurement |
| ☐ | ☒ A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly |
| ☐ | ☒ The statistical test(s) used AND whether they are one- or two-sided
<i>Only common tests should be described solely by name; describe more complex techniques in the Methods section.</i> |
| ☐ | ☒ A description of all covariates tested |
| ☐ | ☒ A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons |
| ☐ | ☒ A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) |
| ☐ | ☒ For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted
<i>Give P values as exact values whenever suitable.</i> |
| ☒ | ☐ For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings |
| ☒ | ☐ For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes |
| ☐ | ☒ Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i>), indicating how they were calculated |

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection	Image acquisition was performed using the NIS software (version 5.01), SmartSEM software (version 7.02 service pack 3) and ZEN software (version14.0.2.201). NMR data were acquired using the Topspin 4.1.4 software. Seahorse measurements were acquired on the Wave software (version 2.6.1.56).
Data analysis	For the single-cell and bulk RNAseq analysis the following software were used: Zebrafish Genome assembly, Zebrafish gene annotation, Mexican tetra genome assembly, Mexican tetra gene annotation, Metascape, Kyoto Encyclopedia of Genes and Genomes (KEGG), EnrichR v.3.4.0, troppo v.0.0.7, RaceID2/StemID, Rstudio, R (v.4.0.1), Bcl2fastq (v2.20.0), Trim Galore! (v.0.6.4_dev), STAR (v.2.7.6a), DESeq2, RUVg, Benjamini-Hochberg algorithm, Pheatmap (R package v1.0.8), Vennerable (R package v2.2/r79) gplots, Seurat (v3.2.2), Monocle2 (v2.18.0), DAVID, StemID2. For the analysis of the NMR results, MestReNova (Mnova, v16.0.0) was used. Image analysis was performed using ImageJ and Amira (v6.7.0). Data visualisation and statistical analysis was performed using GraphPad Prism v9.10.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

The RNAseq datasets generated in this study are deposited in the GEO repository under a SuperSeries with accession number GSE234990 (wild-type strains bulk RNAseq GSE234990; Astyanax bulk RNAseq GSE234989; scRNAseq GSE237276). Published datasets re-analysed in this study come from the following studies: Hu et al. (GSE159032), Honkoop et al. (GSE139218) and Hill et al. (SRP117696). The raw data/measurements presented in this study are provided in the source data table. The materials used in this study are provided in the key resources table. Any further queries may be directed to the corresponding author, Mathilda Mommersteeg (mathilda.mommersteeg@dpag.ox.ac.uk).

Research involving human participants, their data, or biological material

Policy information about studies with [human participants or human data](#). See also policy information about [sex, gender \(identity/presentation\), and sexual orientation](#) and [race, ethnicity and racism](#).

Reporting on sex and gender

Use the terms *sex* (biological attribute) and *gender* (shaped by social and cultural circumstances) carefully in order to avoid confusing both terms. Indicate if findings apply to only one sex or gender; describe whether sex and gender were considered in study design; whether sex and/or gender was determined based on self-reporting or assigned and methods used. Provide in the source data disaggregated sex and gender data, where this information has been collected, and if consent has been obtained for sharing of individual-level data; provide overall numbers in this Reporting Summary. Please state if this information has not been collected.
Report sex- and gender-based analyses where performed, justify reasons for lack of sex- and gender-based analysis.

Reporting on race, ethnicity, or other socially relevant groupings

Please specify the socially constructed or socially relevant categorization variable(s) used in your manuscript and explain why they were used. Please note that such variables should not be used as proxies for other socially constructed/relevant variables (for example, race or ethnicity should not be used as a proxy for socioeconomic status). Provide clear definitions of the relevant terms used, how they were provided (by the participants/respondents, the researchers, or third parties), and the method(s) used to classify people into the different categories (e.g. self-report, census or administrative data, social media data, etc.)
Please provide details about how you controlled for confounding variables in your analyses.

Population characteristics

Describe the covariate-relevant population characteristics of the human research participants (e.g. age, genotypic information, past and current diagnosis and treatment categories). If you filled out the behavioural & social sciences study design questions and have nothing to add here, write "See above."

Recruitment

Describe how participants were recruited. Outline any potential self-selection bias or other biases that may be present and how these are likely to impact results.

Ethics oversight

Identify the organization(s) that approved the study protocol.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

☒ Life sciences ☐ Behavioural & social sciences ☐ Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	Sample sizes were determined based on previous experiments and power calculations. At least three biological replicates were performed for each experiment with the exception of the 1Dpci TU and SAT bulk RNAseq where only two biological replicates were used.
Data exclusions	No data was excluded from our analyses.
Replication	Each experiment includes measurements from several individuals which confirm our findings. Some of our experiments contain individuals from different generations (age matched) which show consistent results.
Randomization	No formal randomisation technique was used, but fish were allocated at random to the different experiments performed and the various timepoints for heart collection.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

- n/a Involved in the study
- ☐ ☒ Antibodies
- ☒ ☐ Eukaryotic cell lines
- ☒ ☐ Palaeontology and archaeology
- ☐ ☒ Animals and other organisms
- ☒ ☐ Clinical data
- ☒ ☐ Dual use research of concern
- ☒ ☐ Plants

Methods

- n/a Involved in the study
- ☒ ☐ ChIP-seq
- ☒ ☐ Flow cytometry
- ☒ ☐ MRI-based neuroimaging

Antibodies

Antibodies used

Primary antibodies Mef2c (Biorbyt, orb576282), PCNA (Clone PC10, Dako, M0879), MF20 (DSHB, AB_2147781), GFP (abcam, ab13970) and embcmhc N2.261 (DSHB, AB_531790), and secondary antibodies, Alexa Fluor® 488 (Invitrogen, A11001, A21206 and A11039) and Alexa Fluor® 555 (Invitrogen, A31570), were prepared using TNB buffer at ratio of 1:200.

Validation

MF-20 (DSHB, AB_2147781) was validated in zebrafish by the manufacturer (<https://dshb.biology.uiowa.edu/MF-20>). Mef2c (Biorbyt, orb576282) validated in human and mice and is predicted to react with zebrafish mef2c by the manufacturer (<https://www.generon.co.uk/other-products-186/mef2c-antibody-716721721.html>). PCNA (Dako Cytomation, M0879) was validated in zebrafish by the manufacturer (<https://www.labome.com/product/Dako/M0879.html>). anti-GFP is reactive to GFP of Aequorea victoria and is the most highly cited GFP antibody (>4700 times) according to the manufacturer (https://www.abcam.com/en-us/products/primary-antibodies/gfp-antibody-ab13970?srsltid=AfmBOorvAUnas-1dvfTvdVoRQ9WaAQNApgo667JVncLiTop2_aZFalep#). N2.261 (DSHB, AB_531790) was validated in zebrafish by the manufacturer (<https://dshb.biology.uiowa.edu/N2-261>). Secondary antibodies were validated by the manufacturer against the host of the primary antibodies, are highly cited and widely used.

Animals and other research organisms

Policy information about [studies involving animals](#): [ARRIVE guidelines](#) recommended for reporting animal research, and [Sex and Gender in Research](#)

Laboratory animals

Danio rerio (zebrafish, strains: AB, NA, SAT, TL, TU, WIK and KCL) and Astyanax mexicanus (Mexican tetra, surface fish and Pachon cavefish) were used in this study. Experiments were performed on fish aged 0.5-2 years. Additionally, the zebrafish transgenic line TgBAC(nppa:mCitrine) (on a TL background) was used for the scRNAseq experiment, mdh1ab cOE and GFP cOE lines were created on the KCL background, and cardiodeleter, mdh1aa cKO and mdh1ab cKO strains were generated on the AB background. When analysing previously published datasets the strain of zebrafish is noted in the manuscript.

Wild animals

The study did not involve wild animals.

Reporting on sex

Both male and female fish were used in our experiments.

Field-collected samples

The study did not involve samples collected from the field.

Ethics oversight

All procedures involving animals at the University of Oxford, Boston College and Hubrecht Institute were approved by the local animal experiment committees and performed in compliance with animal welfare laws, guidelines and policies according to national and European law.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Plants

Seed stocks	<i>Report on the source of all seed stocks or other plant material used. If applicable, state the seed stock centre and catalogue number. If plant specimens were collected from the field, describe the collection location, date and sampling procedures.</i>
Novel plant genotypes	<i>Describe the methods by which all novel plant genotypes were produced. This includes those generated by transgenic approaches, gene editing, chemical/radiation-based mutagenesis and hybridization. For transgenic lines, describe the transformation method, the number of independent lines analyzed and the generation upon which experiments were performed. For gene-edited lines, describe the editor used, the endogenous sequence targeted for editing, the targeting guide RNA sequence (if applicable) and how the editor was applied.</i>
Authentication	<i>Describe any authentication procedures for each seed stock used or novel genotype generated. Describe any experiments used to assess the effect of a mutation and, where applicable, how potential secondary effects (e.g. second site T-DNA insertions, mosaicism, off-target gene editing) were examined.</i>